User login
Cystic Nodule on the Palm
The Diagnosis: Nodular Hidradenoma
Nodular hidradenomas (NHs) are rare benign cutaneous adnexal neoplasms first described in 1949 as clear cell papillary carcinomas.1 Since then, various terms have been used to describe this entity, such as eccrine acrospiroma, solid-cystic hidradenoma, and clear cell hidradenoma.2 Review of the literature revealed a female predominance (2:1 ratio) and a mean age at presentation of 37.2 years.3,4 Nodular hidradenoma presents as an asymptomatic, solitary, mobile, firm nodule with intact overlying skin. Rarely, multiple nodules may occur.3 Some tumors display ulceration and serous fluid leakage.5 They occur most commonly on the scalp, face, and upper extremities with an average size of 2 cm.3 Rapid growth of the tumor may signal a malignant change.6
Histopathology reveals a lobulated, circumscribed, symmetrical tumor with dermal nests of epithelial cells that are polygonal with eosinophilic cytoplasm forming ductlike spaces (Figure). However, clear cell changes and squamous differentiation may be prominent features. Cystic spaces may result from tumor cell degeneration. Most tumors are encased by collagenous fibrous tissue and rarely have epidermal attachments.3
Anastomosing aggregates of squamous cells forming ductlike spaces were viewed on low-power magnification (A)(H&E, original magnification ×10). On higher power there were ductlike spaces and eosinophilic hyalinized stroma entrapped by the bland-appearing squamous proliferation (B)(H&E, original magnification ×20). |
Nodular hidradenoma traditionally has been considered to be of eccrine origin, but more recent literature indicates that the majority of NHs are of apocrine origin. Histologically, apocrine tumors display eosinophilic secretion, mucinous epithelium, squamous or sebaceous differentiation, and decapitation secretion, whereas eccrine tumors are identified by their lack of specific features.3
Nodular hidradenoma may recur after excision. Malignant transformation is rare. In one review, 6.7% (6/89) of NHs were malignant, characterized by abnormal mitoses, nuclear atypia, and necrosis.4 Malignant NH or nodular hidradenocarcinoma behaves aggressively with up to an 86% local recurrence and 60% rate of metastasis within 2 years.6 Survival time is inversely proportional to the size of the tumor and is generally poor, with a 5-year disease-free survival of less than 30%.6,7
Treatment of NH is achieved through primary excision or Mohs micrographic surgery; however, treatment of nodular hidradenocarcinoma is controversial and typically begins with wide local excision but may involve lymph node dissection if necessary. Use of adjuvant chemotherapy and radiation therapy for metastases warrants more clinical studies, as it is a rare occurrence.6 Our patient planned to undergo a total excision of the benign nodule once she healed from the biopsy; however, she was lost to follow-up, as she moved out of state.
1. Lui Y. The histogenesis of clear cell papillary carcinoma of the skin. Am J Pathol. 1949;25:93-103.
2. Obaidat NA, Khaled OA, Ghazarian D. Skin adnexal neoplasms–part 2: an approach to tumours of cutaneous sweat glands. J Clin Pathol. 2007;60:145-159.
3. Nandeesh BN, Rajalakshmi T. A study of histopathologic spectrum of nodular hidradenoma. Am J Dermatopathol. 2012;34:461-470.
4. Hernández-Pérez E, Cestoni-Parducci R. Nodular hidradenoma and hidradenocarcinoma: a 10-year review. J Am Acad Dermatol. 1985;12:15-20.
5. Sirinoglu H, Celebiler O. Benign nodular hidradenoma of the face. J Craniofac Surg. 2011;22:750-751.
6. Souvatzidis P, Sbano P, Mandato F, et al. Malignant nodular hidradenoma of the skin: report of seven cases. J Eur Acad Dermatol Venereol. 2008;22:549-554.
7. Ko CJ, Cochran AJ, Eng W, et al. Hidradenocarcinoma: a histological and immunohistochemical study. J Cutan Pathol. 2006;33:726-730.
The Diagnosis: Nodular Hidradenoma
Nodular hidradenomas (NHs) are rare benign cutaneous adnexal neoplasms first described in 1949 as clear cell papillary carcinomas.1 Since then, various terms have been used to describe this entity, such as eccrine acrospiroma, solid-cystic hidradenoma, and clear cell hidradenoma.2 Review of the literature revealed a female predominance (2:1 ratio) and a mean age at presentation of 37.2 years.3,4 Nodular hidradenoma presents as an asymptomatic, solitary, mobile, firm nodule with intact overlying skin. Rarely, multiple nodules may occur.3 Some tumors display ulceration and serous fluid leakage.5 They occur most commonly on the scalp, face, and upper extremities with an average size of 2 cm.3 Rapid growth of the tumor may signal a malignant change.6
Histopathology reveals a lobulated, circumscribed, symmetrical tumor with dermal nests of epithelial cells that are polygonal with eosinophilic cytoplasm forming ductlike spaces (Figure). However, clear cell changes and squamous differentiation may be prominent features. Cystic spaces may result from tumor cell degeneration. Most tumors are encased by collagenous fibrous tissue and rarely have epidermal attachments.3
Anastomosing aggregates of squamous cells forming ductlike spaces were viewed on low-power magnification (A)(H&E, original magnification ×10). On higher power there were ductlike spaces and eosinophilic hyalinized stroma entrapped by the bland-appearing squamous proliferation (B)(H&E, original magnification ×20). |
Nodular hidradenoma traditionally has been considered to be of eccrine origin, but more recent literature indicates that the majority of NHs are of apocrine origin. Histologically, apocrine tumors display eosinophilic secretion, mucinous epithelium, squamous or sebaceous differentiation, and decapitation secretion, whereas eccrine tumors are identified by their lack of specific features.3
Nodular hidradenoma may recur after excision. Malignant transformation is rare. In one review, 6.7% (6/89) of NHs were malignant, characterized by abnormal mitoses, nuclear atypia, and necrosis.4 Malignant NH or nodular hidradenocarcinoma behaves aggressively with up to an 86% local recurrence and 60% rate of metastasis within 2 years.6 Survival time is inversely proportional to the size of the tumor and is generally poor, with a 5-year disease-free survival of less than 30%.6,7
Treatment of NH is achieved through primary excision or Mohs micrographic surgery; however, treatment of nodular hidradenocarcinoma is controversial and typically begins with wide local excision but may involve lymph node dissection if necessary. Use of adjuvant chemotherapy and radiation therapy for metastases warrants more clinical studies, as it is a rare occurrence.6 Our patient planned to undergo a total excision of the benign nodule once she healed from the biopsy; however, she was lost to follow-up, as she moved out of state.
The Diagnosis: Nodular Hidradenoma
Nodular hidradenomas (NHs) are rare benign cutaneous adnexal neoplasms first described in 1949 as clear cell papillary carcinomas.1 Since then, various terms have been used to describe this entity, such as eccrine acrospiroma, solid-cystic hidradenoma, and clear cell hidradenoma.2 Review of the literature revealed a female predominance (2:1 ratio) and a mean age at presentation of 37.2 years.3,4 Nodular hidradenoma presents as an asymptomatic, solitary, mobile, firm nodule with intact overlying skin. Rarely, multiple nodules may occur.3 Some tumors display ulceration and serous fluid leakage.5 They occur most commonly on the scalp, face, and upper extremities with an average size of 2 cm.3 Rapid growth of the tumor may signal a malignant change.6
Histopathology reveals a lobulated, circumscribed, symmetrical tumor with dermal nests of epithelial cells that are polygonal with eosinophilic cytoplasm forming ductlike spaces (Figure). However, clear cell changes and squamous differentiation may be prominent features. Cystic spaces may result from tumor cell degeneration. Most tumors are encased by collagenous fibrous tissue and rarely have epidermal attachments.3
Anastomosing aggregates of squamous cells forming ductlike spaces were viewed on low-power magnification (A)(H&E, original magnification ×10). On higher power there were ductlike spaces and eosinophilic hyalinized stroma entrapped by the bland-appearing squamous proliferation (B)(H&E, original magnification ×20). |
Nodular hidradenoma traditionally has been considered to be of eccrine origin, but more recent literature indicates that the majority of NHs are of apocrine origin. Histologically, apocrine tumors display eosinophilic secretion, mucinous epithelium, squamous or sebaceous differentiation, and decapitation secretion, whereas eccrine tumors are identified by their lack of specific features.3
Nodular hidradenoma may recur after excision. Malignant transformation is rare. In one review, 6.7% (6/89) of NHs were malignant, characterized by abnormal mitoses, nuclear atypia, and necrosis.4 Malignant NH or nodular hidradenocarcinoma behaves aggressively with up to an 86% local recurrence and 60% rate of metastasis within 2 years.6 Survival time is inversely proportional to the size of the tumor and is generally poor, with a 5-year disease-free survival of less than 30%.6,7
Treatment of NH is achieved through primary excision or Mohs micrographic surgery; however, treatment of nodular hidradenocarcinoma is controversial and typically begins with wide local excision but may involve lymph node dissection if necessary. Use of adjuvant chemotherapy and radiation therapy for metastases warrants more clinical studies, as it is a rare occurrence.6 Our patient planned to undergo a total excision of the benign nodule once she healed from the biopsy; however, she was lost to follow-up, as she moved out of state.
1. Lui Y. The histogenesis of clear cell papillary carcinoma of the skin. Am J Pathol. 1949;25:93-103.
2. Obaidat NA, Khaled OA, Ghazarian D. Skin adnexal neoplasms–part 2: an approach to tumours of cutaneous sweat glands. J Clin Pathol. 2007;60:145-159.
3. Nandeesh BN, Rajalakshmi T. A study of histopathologic spectrum of nodular hidradenoma. Am J Dermatopathol. 2012;34:461-470.
4. Hernández-Pérez E, Cestoni-Parducci R. Nodular hidradenoma and hidradenocarcinoma: a 10-year review. J Am Acad Dermatol. 1985;12:15-20.
5. Sirinoglu H, Celebiler O. Benign nodular hidradenoma of the face. J Craniofac Surg. 2011;22:750-751.
6. Souvatzidis P, Sbano P, Mandato F, et al. Malignant nodular hidradenoma of the skin: report of seven cases. J Eur Acad Dermatol Venereol. 2008;22:549-554.
7. Ko CJ, Cochran AJ, Eng W, et al. Hidradenocarcinoma: a histological and immunohistochemical study. J Cutan Pathol. 2006;33:726-730.
1. Lui Y. The histogenesis of clear cell papillary carcinoma of the skin. Am J Pathol. 1949;25:93-103.
2. Obaidat NA, Khaled OA, Ghazarian D. Skin adnexal neoplasms–part 2: an approach to tumours of cutaneous sweat glands. J Clin Pathol. 2007;60:145-159.
3. Nandeesh BN, Rajalakshmi T. A study of histopathologic spectrum of nodular hidradenoma. Am J Dermatopathol. 2012;34:461-470.
4. Hernández-Pérez E, Cestoni-Parducci R. Nodular hidradenoma and hidradenocarcinoma: a 10-year review. J Am Acad Dermatol. 1985;12:15-20.
5. Sirinoglu H, Celebiler O. Benign nodular hidradenoma of the face. J Craniofac Surg. 2011;22:750-751.
6. Souvatzidis P, Sbano P, Mandato F, et al. Malignant nodular hidradenoma of the skin: report of seven cases. J Eur Acad Dermatol Venereol. 2008;22:549-554.
7. Ko CJ, Cochran AJ, Eng W, et al. Hidradenocarcinoma: a histological and immunohistochemical study. J Cutan Pathol. 2006;33:726-730.
A 73-year-old woman with a history of multiple strokes with residual left-sided motor deficits and resultant left-hand contracture, type 2 diabetes mellitus, hypertension, and a remote history of treated colon cancer and breast cancer presented with hypertensive urgency and neck pain. Upon admission, the nursing staff found an “unusual growth” on the patient’s left hand. Dermatology was consulted and a 2×1.5×1.5-cm multilobulated, malodorous, slightly tender, nonfluctuant, gelatinous, mobile, cystic nodule overlying the fourth metacarpal palmar head was examined. The patient reported the lesion was present for more than a year. Imaging was pursued, but radiography, ultrasonography, and magnetic resonance imaging could not be performed adequately due to the patient’s severe contracture. Given the extensive differential diagnoses, an orthopedic hand surgeon performed a large incisional biopsy to obtain tissue diagnosis.
Firm Plaques and Nodules Over the Body
The Diagnosis: Pancreatic Panniculitis
The biopsy specimen revealed necrosis of the panniculus with “ghost” cells (Figure). Calcification was encountered. Changes of vasculitis were not identified and fungal organisms were not noted. The histopathologic findings supported a diagnosis of pancreatic panniculitis.
Pancreatic panniculitis has been associated with pancreatitis, pancreatic carcinoma, pancreatic pseudocysts, congenital abnormalities of the pancreas, and drug-induced pancreatitis.1 Skin lesions may herald a diagnosis of pancreatic disease in an outpatient and should prompt thorough clinical evaluation when encountered in an outpatient setting. Our patient first developed tender nodules on the left shin 2 to 3 weeks prior to presentation. She reported that her initial nodules were flesh colored but then became erythematous and tender over 1 week’s time. The patient’s history was remarkable for ovarian cancer. She had been hospitalized 2 weeks prior to presentation for abdominal pain and ascites. Imaging studies revealed a cystic lesion in the head of the pancreas. The pancreas was traumatized during a peritoneal tap. Her nodules developed shortly thereafter and were distributed on the arms, legs, back, and abdomen.
Pancreatic tumors or inflammation are thought to trigger pancreatic panniculitis by releasing enzymes. Pancreatic enzymes such as lipase are thought to play a role in the development of pancreatic panniculitis by entering the vascular system and leading to fat necrosis.2,3 Biopsy reveals necrosis of adipocytes in the center of fat lobules.4 Ghost cells result from hydrolytic activity of enzymes on the fat cells followed by calcium deposition. A report indicates that fungal infection or gout also can cause changes that mimic pancreatic panniculitis.5
Other entities in the differential diagnosis can be excluded by biopsy. Polyarteritis nodosa is a vasculitis. Although panniculitis may be seen in polyarteritis as a secondary phenomenon, lesions are centered around blood vessels and often eventuate in ulceration.6 Subcutaneous fungal infection typically reveals organisms on periodic acid–Schiff stain.7 Pyoderma gangrenosum is associated with ulceration and a neutrophilic infiltrate that is often centered around a central pilosebaceous unit in developing lesions.8 Erythema nodosum is a panniculitis in which septal inflammation predominates.9 These differential diagnoses of pancreatic panniculitis are summarized in the Table.
Pancreatic panniculitis can be associated with acute arthritis and inflammation of periarticular fat.10 Treatment of pancreatic panniculitis is usually focused on the underlying pancreatic disease.11,12 Our patient benefited from analgesic therapy and her lesions improved on follow-up. Clinicians encountering a patient with new tender nodules should be prompted to perform a biopsy. When histopathologic evaluation reveals ghosted adipocytes, pancreatic panniculitis should be suspected and clinical evaluation undertaken.
1. Garcia-Romero D, Vanaclocha F. Pancreatic panniculitis. Dermatol Clin. 2008;26:465-470.
2. Berman B, Conteas C, Smith B, et al. Fatal pancreatitis presenting with subcutaneous fat necrosis. J Am Acad Dermatol. 1987;17:359-364.
3. Dhawan SS, Jimenez-Acosta F, Poppiti RJ Jr, et al. Subcutaneous fat necrosis associated with pancreatitis: histochemical and electron microscopic findings. Am J Gastroenterol. 1990;85:1025-1028.
4. Cannon JR, Pitha JV, Everett MA. Subcutaneous fat necrosis in pancreatitis. J Cutan Pathol. 1979;6:501-506.
5. Requena L, Sitthinamsuwan P, Santonja C, et al. Cutaneous and mucosal mucormycosis mimicking pancreatic panniculitis and gouty panniculitis. J Am Acad Dermatol. 2012;66:975-984.
6. Grattan CEH. Polyarteritis nodosa. In: Bolognia JL, Jorizzo JL, Schaffer JV, eds. Dermatology. Vol 1. 3rd ed. China: Elsevier Saunders; 2012:405-407.
7. Millett CR, Halpern AV, Heymann WR. Subcutaneous mycoses. In: Bolognia JL, Jorizzo JL, Schaffer JV, eds. Dermatology. Vol 2. 3rd ed. China: Elsevier Saunders; 2012:1266-1273.
8. Moschella SL, Davis MDP. Pyoderma gangrenosum. In: Bolognia JL, Jorizzo JL, Schaffer JV, eds. Dermatology. Vol 1. 3rd ed. China: Elsevier Saunders; 2012:427-431.
9. Patterson JW. Erythema nodosum. In: Bolognia JL, Jorizzo JL, Schaffer JV, eds. Dermatology. Vol 2. 3rd ed. China: Elsevier Saunders; 2012:1641-1645.
10. Patterson JW. Pancreatic panniculitis. In: Bolognia JL, Jorizzo JL, Schaffer JV, eds. Dermatology. Vol 2. 3rd ed. China: Elsevier Saunders; 2012:1649-1650.
11. Requena L, Sanchez Yus E. Panniculitis. part II. mostly lobular panniculitis. J Am Acad Dermatol. 2001;45:325-361.
12. Dahl PR, Su WP, Cullimore KC, et al. Pancreatic panniculitis. J Am Acad Dermatol. 1995;33:413-417.
The Diagnosis: Pancreatic Panniculitis
The biopsy specimen revealed necrosis of the panniculus with “ghost” cells (Figure). Calcification was encountered. Changes of vasculitis were not identified and fungal organisms were not noted. The histopathologic findings supported a diagnosis of pancreatic panniculitis.
Pancreatic panniculitis has been associated with pancreatitis, pancreatic carcinoma, pancreatic pseudocysts, congenital abnormalities of the pancreas, and drug-induced pancreatitis.1 Skin lesions may herald a diagnosis of pancreatic disease in an outpatient and should prompt thorough clinical evaluation when encountered in an outpatient setting. Our patient first developed tender nodules on the left shin 2 to 3 weeks prior to presentation. She reported that her initial nodules were flesh colored but then became erythematous and tender over 1 week’s time. The patient’s history was remarkable for ovarian cancer. She had been hospitalized 2 weeks prior to presentation for abdominal pain and ascites. Imaging studies revealed a cystic lesion in the head of the pancreas. The pancreas was traumatized during a peritoneal tap. Her nodules developed shortly thereafter and were distributed on the arms, legs, back, and abdomen.
Pancreatic tumors or inflammation are thought to trigger pancreatic panniculitis by releasing enzymes. Pancreatic enzymes such as lipase are thought to play a role in the development of pancreatic panniculitis by entering the vascular system and leading to fat necrosis.2,3 Biopsy reveals necrosis of adipocytes in the center of fat lobules.4 Ghost cells result from hydrolytic activity of enzymes on the fat cells followed by calcium deposition. A report indicates that fungal infection or gout also can cause changes that mimic pancreatic panniculitis.5
Other entities in the differential diagnosis can be excluded by biopsy. Polyarteritis nodosa is a vasculitis. Although panniculitis may be seen in polyarteritis as a secondary phenomenon, lesions are centered around blood vessels and often eventuate in ulceration.6 Subcutaneous fungal infection typically reveals organisms on periodic acid–Schiff stain.7 Pyoderma gangrenosum is associated with ulceration and a neutrophilic infiltrate that is often centered around a central pilosebaceous unit in developing lesions.8 Erythema nodosum is a panniculitis in which septal inflammation predominates.9 These differential diagnoses of pancreatic panniculitis are summarized in the Table.
Pancreatic panniculitis can be associated with acute arthritis and inflammation of periarticular fat.10 Treatment of pancreatic panniculitis is usually focused on the underlying pancreatic disease.11,12 Our patient benefited from analgesic therapy and her lesions improved on follow-up. Clinicians encountering a patient with new tender nodules should be prompted to perform a biopsy. When histopathologic evaluation reveals ghosted adipocytes, pancreatic panniculitis should be suspected and clinical evaluation undertaken.
The Diagnosis: Pancreatic Panniculitis
The biopsy specimen revealed necrosis of the panniculus with “ghost” cells (Figure). Calcification was encountered. Changes of vasculitis were not identified and fungal organisms were not noted. The histopathologic findings supported a diagnosis of pancreatic panniculitis.
Pancreatic panniculitis has been associated with pancreatitis, pancreatic carcinoma, pancreatic pseudocysts, congenital abnormalities of the pancreas, and drug-induced pancreatitis.1 Skin lesions may herald a diagnosis of pancreatic disease in an outpatient and should prompt thorough clinical evaluation when encountered in an outpatient setting. Our patient first developed tender nodules on the left shin 2 to 3 weeks prior to presentation. She reported that her initial nodules were flesh colored but then became erythematous and tender over 1 week’s time. The patient’s history was remarkable for ovarian cancer. She had been hospitalized 2 weeks prior to presentation for abdominal pain and ascites. Imaging studies revealed a cystic lesion in the head of the pancreas. The pancreas was traumatized during a peritoneal tap. Her nodules developed shortly thereafter and were distributed on the arms, legs, back, and abdomen.
Pancreatic tumors or inflammation are thought to trigger pancreatic panniculitis by releasing enzymes. Pancreatic enzymes such as lipase are thought to play a role in the development of pancreatic panniculitis by entering the vascular system and leading to fat necrosis.2,3 Biopsy reveals necrosis of adipocytes in the center of fat lobules.4 Ghost cells result from hydrolytic activity of enzymes on the fat cells followed by calcium deposition. A report indicates that fungal infection or gout also can cause changes that mimic pancreatic panniculitis.5
Other entities in the differential diagnosis can be excluded by biopsy. Polyarteritis nodosa is a vasculitis. Although panniculitis may be seen in polyarteritis as a secondary phenomenon, lesions are centered around blood vessels and often eventuate in ulceration.6 Subcutaneous fungal infection typically reveals organisms on periodic acid–Schiff stain.7 Pyoderma gangrenosum is associated with ulceration and a neutrophilic infiltrate that is often centered around a central pilosebaceous unit in developing lesions.8 Erythema nodosum is a panniculitis in which septal inflammation predominates.9 These differential diagnoses of pancreatic panniculitis are summarized in the Table.
Pancreatic panniculitis can be associated with acute arthritis and inflammation of periarticular fat.10 Treatment of pancreatic panniculitis is usually focused on the underlying pancreatic disease.11,12 Our patient benefited from analgesic therapy and her lesions improved on follow-up. Clinicians encountering a patient with new tender nodules should be prompted to perform a biopsy. When histopathologic evaluation reveals ghosted adipocytes, pancreatic panniculitis should be suspected and clinical evaluation undertaken.
1. Garcia-Romero D, Vanaclocha F. Pancreatic panniculitis. Dermatol Clin. 2008;26:465-470.
2. Berman B, Conteas C, Smith B, et al. Fatal pancreatitis presenting with subcutaneous fat necrosis. J Am Acad Dermatol. 1987;17:359-364.
3. Dhawan SS, Jimenez-Acosta F, Poppiti RJ Jr, et al. Subcutaneous fat necrosis associated with pancreatitis: histochemical and electron microscopic findings. Am J Gastroenterol. 1990;85:1025-1028.
4. Cannon JR, Pitha JV, Everett MA. Subcutaneous fat necrosis in pancreatitis. J Cutan Pathol. 1979;6:501-506.
5. Requena L, Sitthinamsuwan P, Santonja C, et al. Cutaneous and mucosal mucormycosis mimicking pancreatic panniculitis and gouty panniculitis. J Am Acad Dermatol. 2012;66:975-984.
6. Grattan CEH. Polyarteritis nodosa. In: Bolognia JL, Jorizzo JL, Schaffer JV, eds. Dermatology. Vol 1. 3rd ed. China: Elsevier Saunders; 2012:405-407.
7. Millett CR, Halpern AV, Heymann WR. Subcutaneous mycoses. In: Bolognia JL, Jorizzo JL, Schaffer JV, eds. Dermatology. Vol 2. 3rd ed. China: Elsevier Saunders; 2012:1266-1273.
8. Moschella SL, Davis MDP. Pyoderma gangrenosum. In: Bolognia JL, Jorizzo JL, Schaffer JV, eds. Dermatology. Vol 1. 3rd ed. China: Elsevier Saunders; 2012:427-431.
9. Patterson JW. Erythema nodosum. In: Bolognia JL, Jorizzo JL, Schaffer JV, eds. Dermatology. Vol 2. 3rd ed. China: Elsevier Saunders; 2012:1641-1645.
10. Patterson JW. Pancreatic panniculitis. In: Bolognia JL, Jorizzo JL, Schaffer JV, eds. Dermatology. Vol 2. 3rd ed. China: Elsevier Saunders; 2012:1649-1650.
11. Requena L, Sanchez Yus E. Panniculitis. part II. mostly lobular panniculitis. J Am Acad Dermatol. 2001;45:325-361.
12. Dahl PR, Su WP, Cullimore KC, et al. Pancreatic panniculitis. J Am Acad Dermatol. 1995;33:413-417.
1. Garcia-Romero D, Vanaclocha F. Pancreatic panniculitis. Dermatol Clin. 2008;26:465-470.
2. Berman B, Conteas C, Smith B, et al. Fatal pancreatitis presenting with subcutaneous fat necrosis. J Am Acad Dermatol. 1987;17:359-364.
3. Dhawan SS, Jimenez-Acosta F, Poppiti RJ Jr, et al. Subcutaneous fat necrosis associated with pancreatitis: histochemical and electron microscopic findings. Am J Gastroenterol. 1990;85:1025-1028.
4. Cannon JR, Pitha JV, Everett MA. Subcutaneous fat necrosis in pancreatitis. J Cutan Pathol. 1979;6:501-506.
5. Requena L, Sitthinamsuwan P, Santonja C, et al. Cutaneous and mucosal mucormycosis mimicking pancreatic panniculitis and gouty panniculitis. J Am Acad Dermatol. 2012;66:975-984.
6. Grattan CEH. Polyarteritis nodosa. In: Bolognia JL, Jorizzo JL, Schaffer JV, eds. Dermatology. Vol 1. 3rd ed. China: Elsevier Saunders; 2012:405-407.
7. Millett CR, Halpern AV, Heymann WR. Subcutaneous mycoses. In: Bolognia JL, Jorizzo JL, Schaffer JV, eds. Dermatology. Vol 2. 3rd ed. China: Elsevier Saunders; 2012:1266-1273.
8. Moschella SL, Davis MDP. Pyoderma gangrenosum. In: Bolognia JL, Jorizzo JL, Schaffer JV, eds. Dermatology. Vol 1. 3rd ed. China: Elsevier Saunders; 2012:427-431.
9. Patterson JW. Erythema nodosum. In: Bolognia JL, Jorizzo JL, Schaffer JV, eds. Dermatology. Vol 2. 3rd ed. China: Elsevier Saunders; 2012:1641-1645.
10. Patterson JW. Pancreatic panniculitis. In: Bolognia JL, Jorizzo JL, Schaffer JV, eds. Dermatology. Vol 2. 3rd ed. China: Elsevier Saunders; 2012:1649-1650.
11. Requena L, Sanchez Yus E. Panniculitis. part II. mostly lobular panniculitis. J Am Acad Dermatol. 2001;45:325-361.
12. Dahl PR, Su WP, Cullimore KC, et al. Pancreatic panniculitis. J Am Acad Dermatol. 1995;33:413-417.
A 52-year-old woman presented with painful erythematous nodules of 2 weeks’ duration that began as a single lesion on the left shin and spread rapidly to involve the trunk, arms, and legs. A punch biopsy was performed. Pertinent history included a recent hospitalization for drainage of malignant ascites secondary to metastatic ovarian cancer. The lesions did not drain and were not pruritic. The patient did not have a history of fever, night sweats, nausea, headache, neurologic change, muscle aching, or recent weight loss.
What Is Your Diagnosis? Onychomadesis Following Hand-foot-and-mouth Disease
The Diagnosis: Onychomadesis Following Hand-foot-and-mouth Disease
In 1846, Joseph Honoré Simon Beau described specific diagnostic signs manifested in the nails during various disease states.1 He suggested that the width of the nail plate depression correlated with the duration of illness. Since then, the correlation of nail changes during times of illness has been confirmed. The term Beau lines currently is used to describe transverse ridging of the nail plate due to transient arrest in nail plate formation.1 Onychomadesis is believed to be an extreme form of Beau lines in which the whole thickness of the nail plate is affected, resulting in its separation from the proximal nail fold and shedding of the nail plate.
Nail plate detachment in onychomadesis is due to a severe insult that results in complete arrest of the nail matrix activity. Onychomadesis has a wide spectrum of clinical presentations, ranging from mild transverse ridges of the nail plate (Beau lines) to complete nail shedding.2 Trauma is the leading cause of single-digit onychomadesis, while multiple-digit onychomadesis usually is caused by a systemic disease (eg, blistering illnesses). Cases of multiple-nail onychomadesis have been reported following hand-foot-and-mouth disease (HFMD), though the majority of cases of HFMD do not present with onychomadesis.
Hand-foot-and-mouth disease is most commonly caused by 2 types of intestinal strains of Human enterovirus A: (1) coxsackievirus A6 (CVA6) or A16 (CVA16) and (2) enterovirus 71.3,4 Symptoms of HFMD include fever and sore throat followed by the development of oral ulcerations 1 to 2 days later. A vesicular or maculopapular rash can then develop on the hands, feet, and mouth. Complications following HFMD are rare but can include encephalitis, meningitis, and pneumonia. Symptoms typically resolve after 6 days without any treatment.3
A cluster of onychomadesis cases following HFMD outbreaks have been reported in Europe, Asia, and the United States. In some reports, causative viral strains have been identified. After a national HFMD outbreak in Finland in fall 2008, investigators isolated strains of CVA6 in the shedded nails of sibling patients.4 The CVA6 strain was found to be the primary pathogen causing that particular HFMD outbreak and onychomadesis was a hallmark presentation of this viral epidemic. Previously, HFMD outbreaks were known to be caused by CVA16 or enterovirus 71, with enterovirus 71 strains occurring mostly in Southeast Asia and Australia.4 In a report from Taiwan, the incidence of onychomadesis after CVA6 infection was 37% (48/130) as compared to 5% (7/145) in cases with non-CVA6 causative strains. Among patients with onychomadesis, 69% (33/48) were reported to experience concurrent palmoplantar desquamation before or during presentation of nail changes.5
Another Finnish study investigated an atypical outbreak of HFMD that occurred primarily in adult patients.6 Many of these patients also had onychomadesis several weeks following HFMD. Of 317 cases, human enteroviruses were detected in specimens from 212 cases (67%), including both children and adults. Two human enterovirus types—CVA6 (71% [83/117]) and coxsackievirus A10 (28% [33/117])—were identified as the causative agents of the outbreak. One genetic variant of CVA6 predominated, but 3 other genetically distinct CVA6 strains also were found.6 The 2008 HFMD outbreak in Finland was found to be caused by 2 concomitantly circulating human enteroviruses, which up until now have been infrequently detected together as causative agents of HFMD. Onychomadesis was a common occurrence in the Finnish HFMD outbreak, which has been previously linked to CVA6. The co-circulation of CVA6 and coxsackievirus A10 suggests an endemic emergence of new genetic variants of these enteroviruses.6
There also have been several reports of onychomadesis outbreaks in Spain, 2 of which occurred in nursery settings. One report noted that patients with a history of HFMD were 14 times more likely to develop onychomadesis (relative risk, 14; 95% confidence interval, 4.57-42.86).3 There also was a noted difference in prevalence of onychomadesis regarding age: a 55% (18/33) occurrence rate was noted in the youngest age group (9–23 months), 30% (8/27) in the middle age group (24–32 months), and 4% (1/28) in the oldest age group (33–42 months). Occurrence of onychomadesis and nail plate changes was observed on average 40 days after HFMD, and an average of 4 nails were shed per case.3 A report investigating a separate HFMD outbreak in Spain found a high percentage of onychomadesis (96% [298/311]) occurring in children younger than 6 years. This outbreak, which occurred in the metropolitan area of Valencia, was associated with an outbreak of HFMD primarily caused by coxsackievirus A10.7 A third Spanish study uncovered a high occurrence of onychomadesis in a nursery setting as a consequence of HFMD, where 92% (11/12) of onychomadesis cases were preceded by HFMD 2 months prior.8
A case series reported in Chicago, Illinois, in the late 1990s identified 5 pediatric patients with HFMD associated with Beau lines and onychomadesis.1 Only 3 of 5 (60%) patients had a fever; therefore, fever-induced nail matrix arrest was ruled out as the inciting factor of the nail changes seen. All patients were given over-the-counter analgesics and 2 received antibiotics (amoxicillin for the first 48 hours). None of these medications have been implicated as plausible causes of nail matrix arrest. Two patients were siblings and the rest were not related. None of the patients had a history of close physical proximity (eg, attendance at the same day care or school). All 5 patients developed HFMD within 4 weeks of one another, and all were from the suburbs of Chicago (with 4 of 5 [80%] patients living within a 60-mile radius of each other). Although the causative viral strain was not isolated, the authors concluded that all the patients were likely to have been infected by the same virus due to the general vicinity of the patients to each other. Furthermore, the collective case reports likely represented an HFMD epidemic caused by a particular strain that can induce onychomadesis.1
Supportive care for the viral illness paired with protection of the nail bed until new nail growth occurs is ideal, which requires maintaining short nails and using adhesive bandages over the affected nails to avoid snagging the nail or ripping off the partially attached nails.
Onychomadesis can follow HFMD, especially in cases caused by CVA6. Cases of onychomadesis are mild and self-limited. When onychomadesis is noted, historical review of viral illnesses within 1 to 2 months prior to nail changes often will identify the causative disease.
- Clementz GC, Mancini AJ. Nail matrix arrest following hand-foot-mouth disease: a report of five children. Pediatr Dermatol. 2000;17:7-11.
- Tosti A, Piraccini BM. Nail disorders. In: Bolognia JL, Jorizzo JL, Rapini RP, eds. Dermatology. China: Elsevier; 2012:1130-1131.
- Guimbao J, Rodrigo P, Alberto MJ, et al. Onychomadesis outbreak linked to hand, foot, and mouth disease, Spain, July 2008. Euro Surveill. 2010;15:19663.
- Osterback R, Vuorinen T, Linna M, et al. Coxsackievirus A6 and hand, foot, and mouth disease, Finland. Emerg Infect Dis. 2009;15:1485-1488.
- Wei SH, Huang YP, Liu MC, et al. An outbreak of coxsackievirus A6 hand, foot, and mouth disease associated with onychomadesis in Taiwan, 2010. BMC Infect Dis. 2011;11:346.
- Blomqvist S, Klemola P, Kaijalainen S, et al. Co-circulation of coxsackieviruses A6 and A10 in hand, foot and mouth disease outbreak in Finland. J Clin Virol. 2010;48:49-54.
- Davia JL, Bel PH, Ninet VZ, et al. Onychomadesis outbreak in Valencia, Spain, associated with hand, foot, and mouth disease caused by enteroviruses. Pediatr Dermatol. 2011;28:1-5.
- Cabrerizo M, De Miguel T, Armada A, et al. Onychomadesis after a hand, foot, and mouth disease outbreak in Spain, 2009. Epidemiol Infect. 2010;138:1775-1778.
The Diagnosis: Onychomadesis Following Hand-foot-and-mouth Disease
In 1846, Joseph Honoré Simon Beau described specific diagnostic signs manifested in the nails during various disease states.1 He suggested that the width of the nail plate depression correlated with the duration of illness. Since then, the correlation of nail changes during times of illness has been confirmed. The term Beau lines currently is used to describe transverse ridging of the nail plate due to transient arrest in nail plate formation.1 Onychomadesis is believed to be an extreme form of Beau lines in which the whole thickness of the nail plate is affected, resulting in its separation from the proximal nail fold and shedding of the nail plate.
Nail plate detachment in onychomadesis is due to a severe insult that results in complete arrest of the nail matrix activity. Onychomadesis has a wide spectrum of clinical presentations, ranging from mild transverse ridges of the nail plate (Beau lines) to complete nail shedding.2 Trauma is the leading cause of single-digit onychomadesis, while multiple-digit onychomadesis usually is caused by a systemic disease (eg, blistering illnesses). Cases of multiple-nail onychomadesis have been reported following hand-foot-and-mouth disease (HFMD), though the majority of cases of HFMD do not present with onychomadesis.
Hand-foot-and-mouth disease is most commonly caused by 2 types of intestinal strains of Human enterovirus A: (1) coxsackievirus A6 (CVA6) or A16 (CVA16) and (2) enterovirus 71.3,4 Symptoms of HFMD include fever and sore throat followed by the development of oral ulcerations 1 to 2 days later. A vesicular or maculopapular rash can then develop on the hands, feet, and mouth. Complications following HFMD are rare but can include encephalitis, meningitis, and pneumonia. Symptoms typically resolve after 6 days without any treatment.3
A cluster of onychomadesis cases following HFMD outbreaks have been reported in Europe, Asia, and the United States. In some reports, causative viral strains have been identified. After a national HFMD outbreak in Finland in fall 2008, investigators isolated strains of CVA6 in the shedded nails of sibling patients.4 The CVA6 strain was found to be the primary pathogen causing that particular HFMD outbreak and onychomadesis was a hallmark presentation of this viral epidemic. Previously, HFMD outbreaks were known to be caused by CVA16 or enterovirus 71, with enterovirus 71 strains occurring mostly in Southeast Asia and Australia.4 In a report from Taiwan, the incidence of onychomadesis after CVA6 infection was 37% (48/130) as compared to 5% (7/145) in cases with non-CVA6 causative strains. Among patients with onychomadesis, 69% (33/48) were reported to experience concurrent palmoplantar desquamation before or during presentation of nail changes.5
Another Finnish study investigated an atypical outbreak of HFMD that occurred primarily in adult patients.6 Many of these patients also had onychomadesis several weeks following HFMD. Of 317 cases, human enteroviruses were detected in specimens from 212 cases (67%), including both children and adults. Two human enterovirus types—CVA6 (71% [83/117]) and coxsackievirus A10 (28% [33/117])—were identified as the causative agents of the outbreak. One genetic variant of CVA6 predominated, but 3 other genetically distinct CVA6 strains also were found.6 The 2008 HFMD outbreak in Finland was found to be caused by 2 concomitantly circulating human enteroviruses, which up until now have been infrequently detected together as causative agents of HFMD. Onychomadesis was a common occurrence in the Finnish HFMD outbreak, which has been previously linked to CVA6. The co-circulation of CVA6 and coxsackievirus A10 suggests an endemic emergence of new genetic variants of these enteroviruses.6
There also have been several reports of onychomadesis outbreaks in Spain, 2 of which occurred in nursery settings. One report noted that patients with a history of HFMD were 14 times more likely to develop onychomadesis (relative risk, 14; 95% confidence interval, 4.57-42.86).3 There also was a noted difference in prevalence of onychomadesis regarding age: a 55% (18/33) occurrence rate was noted in the youngest age group (9–23 months), 30% (8/27) in the middle age group (24–32 months), and 4% (1/28) in the oldest age group (33–42 months). Occurrence of onychomadesis and nail plate changes was observed on average 40 days after HFMD, and an average of 4 nails were shed per case.3 A report investigating a separate HFMD outbreak in Spain found a high percentage of onychomadesis (96% [298/311]) occurring in children younger than 6 years. This outbreak, which occurred in the metropolitan area of Valencia, was associated with an outbreak of HFMD primarily caused by coxsackievirus A10.7 A third Spanish study uncovered a high occurrence of onychomadesis in a nursery setting as a consequence of HFMD, where 92% (11/12) of onychomadesis cases were preceded by HFMD 2 months prior.8
A case series reported in Chicago, Illinois, in the late 1990s identified 5 pediatric patients with HFMD associated with Beau lines and onychomadesis.1 Only 3 of 5 (60%) patients had a fever; therefore, fever-induced nail matrix arrest was ruled out as the inciting factor of the nail changes seen. All patients were given over-the-counter analgesics and 2 received antibiotics (amoxicillin for the first 48 hours). None of these medications have been implicated as plausible causes of nail matrix arrest. Two patients were siblings and the rest were not related. None of the patients had a history of close physical proximity (eg, attendance at the same day care or school). All 5 patients developed HFMD within 4 weeks of one another, and all were from the suburbs of Chicago (with 4 of 5 [80%] patients living within a 60-mile radius of each other). Although the causative viral strain was not isolated, the authors concluded that all the patients were likely to have been infected by the same virus due to the general vicinity of the patients to each other. Furthermore, the collective case reports likely represented an HFMD epidemic caused by a particular strain that can induce onychomadesis.1
Supportive care for the viral illness paired with protection of the nail bed until new nail growth occurs is ideal, which requires maintaining short nails and using adhesive bandages over the affected nails to avoid snagging the nail or ripping off the partially attached nails.
Onychomadesis can follow HFMD, especially in cases caused by CVA6. Cases of onychomadesis are mild and self-limited. When onychomadesis is noted, historical review of viral illnesses within 1 to 2 months prior to nail changes often will identify the causative disease.
The Diagnosis: Onychomadesis Following Hand-foot-and-mouth Disease
In 1846, Joseph Honoré Simon Beau described specific diagnostic signs manifested in the nails during various disease states.1 He suggested that the width of the nail plate depression correlated with the duration of illness. Since then, the correlation of nail changes during times of illness has been confirmed. The term Beau lines currently is used to describe transverse ridging of the nail plate due to transient arrest in nail plate formation.1 Onychomadesis is believed to be an extreme form of Beau lines in which the whole thickness of the nail plate is affected, resulting in its separation from the proximal nail fold and shedding of the nail plate.
Nail plate detachment in onychomadesis is due to a severe insult that results in complete arrest of the nail matrix activity. Onychomadesis has a wide spectrum of clinical presentations, ranging from mild transverse ridges of the nail plate (Beau lines) to complete nail shedding.2 Trauma is the leading cause of single-digit onychomadesis, while multiple-digit onychomadesis usually is caused by a systemic disease (eg, blistering illnesses). Cases of multiple-nail onychomadesis have been reported following hand-foot-and-mouth disease (HFMD), though the majority of cases of HFMD do not present with onychomadesis.
Hand-foot-and-mouth disease is most commonly caused by 2 types of intestinal strains of Human enterovirus A: (1) coxsackievirus A6 (CVA6) or A16 (CVA16) and (2) enterovirus 71.3,4 Symptoms of HFMD include fever and sore throat followed by the development of oral ulcerations 1 to 2 days later. A vesicular or maculopapular rash can then develop on the hands, feet, and mouth. Complications following HFMD are rare but can include encephalitis, meningitis, and pneumonia. Symptoms typically resolve after 6 days without any treatment.3
A cluster of onychomadesis cases following HFMD outbreaks have been reported in Europe, Asia, and the United States. In some reports, causative viral strains have been identified. After a national HFMD outbreak in Finland in fall 2008, investigators isolated strains of CVA6 in the shedded nails of sibling patients.4 The CVA6 strain was found to be the primary pathogen causing that particular HFMD outbreak and onychomadesis was a hallmark presentation of this viral epidemic. Previously, HFMD outbreaks were known to be caused by CVA16 or enterovirus 71, with enterovirus 71 strains occurring mostly in Southeast Asia and Australia.4 In a report from Taiwan, the incidence of onychomadesis after CVA6 infection was 37% (48/130) as compared to 5% (7/145) in cases with non-CVA6 causative strains. Among patients with onychomadesis, 69% (33/48) were reported to experience concurrent palmoplantar desquamation before or during presentation of nail changes.5
Another Finnish study investigated an atypical outbreak of HFMD that occurred primarily in adult patients.6 Many of these patients also had onychomadesis several weeks following HFMD. Of 317 cases, human enteroviruses were detected in specimens from 212 cases (67%), including both children and adults. Two human enterovirus types—CVA6 (71% [83/117]) and coxsackievirus A10 (28% [33/117])—were identified as the causative agents of the outbreak. One genetic variant of CVA6 predominated, but 3 other genetically distinct CVA6 strains also were found.6 The 2008 HFMD outbreak in Finland was found to be caused by 2 concomitantly circulating human enteroviruses, which up until now have been infrequently detected together as causative agents of HFMD. Onychomadesis was a common occurrence in the Finnish HFMD outbreak, which has been previously linked to CVA6. The co-circulation of CVA6 and coxsackievirus A10 suggests an endemic emergence of new genetic variants of these enteroviruses.6
There also have been several reports of onychomadesis outbreaks in Spain, 2 of which occurred in nursery settings. One report noted that patients with a history of HFMD were 14 times more likely to develop onychomadesis (relative risk, 14; 95% confidence interval, 4.57-42.86).3 There also was a noted difference in prevalence of onychomadesis regarding age: a 55% (18/33) occurrence rate was noted in the youngest age group (9–23 months), 30% (8/27) in the middle age group (24–32 months), and 4% (1/28) in the oldest age group (33–42 months). Occurrence of onychomadesis and nail plate changes was observed on average 40 days after HFMD, and an average of 4 nails were shed per case.3 A report investigating a separate HFMD outbreak in Spain found a high percentage of onychomadesis (96% [298/311]) occurring in children younger than 6 years. This outbreak, which occurred in the metropolitan area of Valencia, was associated with an outbreak of HFMD primarily caused by coxsackievirus A10.7 A third Spanish study uncovered a high occurrence of onychomadesis in a nursery setting as a consequence of HFMD, where 92% (11/12) of onychomadesis cases were preceded by HFMD 2 months prior.8
A case series reported in Chicago, Illinois, in the late 1990s identified 5 pediatric patients with HFMD associated with Beau lines and onychomadesis.1 Only 3 of 5 (60%) patients had a fever; therefore, fever-induced nail matrix arrest was ruled out as the inciting factor of the nail changes seen. All patients were given over-the-counter analgesics and 2 received antibiotics (amoxicillin for the first 48 hours). None of these medications have been implicated as plausible causes of nail matrix arrest. Two patients were siblings and the rest were not related. None of the patients had a history of close physical proximity (eg, attendance at the same day care or school). All 5 patients developed HFMD within 4 weeks of one another, and all were from the suburbs of Chicago (with 4 of 5 [80%] patients living within a 60-mile radius of each other). Although the causative viral strain was not isolated, the authors concluded that all the patients were likely to have been infected by the same virus due to the general vicinity of the patients to each other. Furthermore, the collective case reports likely represented an HFMD epidemic caused by a particular strain that can induce onychomadesis.1
Supportive care for the viral illness paired with protection of the nail bed until new nail growth occurs is ideal, which requires maintaining short nails and using adhesive bandages over the affected nails to avoid snagging the nail or ripping off the partially attached nails.
Onychomadesis can follow HFMD, especially in cases caused by CVA6. Cases of onychomadesis are mild and self-limited. When onychomadesis is noted, historical review of viral illnesses within 1 to 2 months prior to nail changes often will identify the causative disease.
- Clementz GC, Mancini AJ. Nail matrix arrest following hand-foot-mouth disease: a report of five children. Pediatr Dermatol. 2000;17:7-11.
- Tosti A, Piraccini BM. Nail disorders. In: Bolognia JL, Jorizzo JL, Rapini RP, eds. Dermatology. China: Elsevier; 2012:1130-1131.
- Guimbao J, Rodrigo P, Alberto MJ, et al. Onychomadesis outbreak linked to hand, foot, and mouth disease, Spain, July 2008. Euro Surveill. 2010;15:19663.
- Osterback R, Vuorinen T, Linna M, et al. Coxsackievirus A6 and hand, foot, and mouth disease, Finland. Emerg Infect Dis. 2009;15:1485-1488.
- Wei SH, Huang YP, Liu MC, et al. An outbreak of coxsackievirus A6 hand, foot, and mouth disease associated with onychomadesis in Taiwan, 2010. BMC Infect Dis. 2011;11:346.
- Blomqvist S, Klemola P, Kaijalainen S, et al. Co-circulation of coxsackieviruses A6 and A10 in hand, foot and mouth disease outbreak in Finland. J Clin Virol. 2010;48:49-54.
- Davia JL, Bel PH, Ninet VZ, et al. Onychomadesis outbreak in Valencia, Spain, associated with hand, foot, and mouth disease caused by enteroviruses. Pediatr Dermatol. 2011;28:1-5.
- Cabrerizo M, De Miguel T, Armada A, et al. Onychomadesis after a hand, foot, and mouth disease outbreak in Spain, 2009. Epidemiol Infect. 2010;138:1775-1778.
- Clementz GC, Mancini AJ. Nail matrix arrest following hand-foot-mouth disease: a report of five children. Pediatr Dermatol. 2000;17:7-11.
- Tosti A, Piraccini BM. Nail disorders. In: Bolognia JL, Jorizzo JL, Rapini RP, eds. Dermatology. China: Elsevier; 2012:1130-1131.
- Guimbao J, Rodrigo P, Alberto MJ, et al. Onychomadesis outbreak linked to hand, foot, and mouth disease, Spain, July 2008. Euro Surveill. 2010;15:19663.
- Osterback R, Vuorinen T, Linna M, et al. Coxsackievirus A6 and hand, foot, and mouth disease, Finland. Emerg Infect Dis. 2009;15:1485-1488.
- Wei SH, Huang YP, Liu MC, et al. An outbreak of coxsackievirus A6 hand, foot, and mouth disease associated with onychomadesis in Taiwan, 2010. BMC Infect Dis. 2011;11:346.
- Blomqvist S, Klemola P, Kaijalainen S, et al. Co-circulation of coxsackieviruses A6 and A10 in hand, foot and mouth disease outbreak in Finland. J Clin Virol. 2010;48:49-54.
- Davia JL, Bel PH, Ninet VZ, et al. Onychomadesis outbreak in Valencia, Spain, associated with hand, foot, and mouth disease caused by enteroviruses. Pediatr Dermatol. 2011;28:1-5.
- Cabrerizo M, De Miguel T, Armada A, et al. Onychomadesis after a hand, foot, and mouth disease outbreak in Spain, 2009. Epidemiol Infect. 2010;138:1775-1778.
Indurated Erythematous Papules and Plaques on the Forearm
The Diagnosis: Mycobacterium chelonae Arising Within a Tattoo
A 3-mm punch biopsy specimen was obtained from one of the plaques. Histopathology revealed an unremarkable epidermis with granulomatous collections of epithelioid histiocytes in association with neutrophils and lymphocytes in the dermis (Figure 1). Periodic acid–Schiff stain was negative for fungal organisms. Gram stain was negative for bacteria. Fite stain was positive for acid-fast bacilli (Figure 2). Clinical and histopathologic findings led to the initial diagnosis of a mycobacterial infection within the tattoo. The patient was empirically started on oral doxycycline 100 mg twice daily and oral clarithromycin 500 mg twice daily with mild improvement of the lesions over the next month. After 6 weeks the mycobacterial cultures were persistently negative and high-performance liquid chromatography was performed verifying the presence of Mycobacterium chelonae. Clarithromycin was continued and the doxycycline was replaced with oral trimethoprim-sulfamethoxazole (double strength) twice daily due to resistance. The patient was referred to an infectious disease specialist who concurred with the treatment regimen for a duration of 6 months to a year. A chest radiograph also was performed to rule out disseminated disease. Several months later the patient’s close friend presented with a similar infection that was acquired on the same day as our patient at the same tattoo parlor. The New York City Department of Health and Mental Hygiene was notified about these cases and informed us of other cases in New York State linked to contaminated tattoo ink.
|
Mycobacterium chelonae is a rapidly growing nontuberculous mycobacteria (Runyon group IV) that is found in nature and contaminated sources such as soil, lakes, sewage, and tap water.1 Inoculation ofM chelonae through contaminated instruments leads to the formation of painful lesions, abscesses, fistulas, and granulomas that are extremely difficult to treat.2 In our patient, M chelonae was most likely transmitted via contaminated tap water that was used to dilute the black tattoo ink to yield a gray color. Alternative sources are the ink itself or the container used to mix the ink.3Mycobacterium chelonae can cause infections in the skin, lungs, joints, bones, and eyes.4 With the exception of lung disease, trauma is the usual inciting factor. Disseminated infections are almost exclusively found in immunosuppressed individuals. Mycobacterium chelonae is typically found to grow on culture within 7 days. However, in our case there was no growth after 6 weeks of incubation. High-performance liquid chromatography analysis of mycolic acid is an alternative method of identifying mycobacteria. This technique verified the presence of M chelonae in our case when cultures were persistently negative.5
Mycobacterium chelonae is difficult to treat. The most common antibiotics used for treatment are clarithromycin, azithromycin, doxycycline, and linezolid.6 Studies of various antibiotics have shown that clarithromycin is the most effective macrolide against M chelonae.7 Tetracyclines also were studied in their effectiveness at treating nontuberculous mycobacteria infections but were found to have increased resistance to M chelonae.8 Although treatment regimens vary, the highest success rates are achieved with a minimum of 6 months of therapy using at least 2 drugs. Longer treatment is recommended for immunocompromised individuals.9
The case we present is important from a public health perspective. The tattoo industry and ink manufacturers should bemade aware of the risks of various infections from nonsterile techniques. Tattoo parlor employees should be advised of the risks of using nonsterile water for ink dilution and cleaning tattoo equipment. They also should be continuously educated on aseptic techniques.
1. Lee RP, Cheung KW, Chiu KH, et al. Mycobacterium chelonae infection after total knee arthroplasty: a case report. J Orthop Surg (Hong Kong). 2012;20:134-136.
2. Camargo D, Saad C, Ruiz F, et al. latrogenic outbreak of M. chelonae skin abscesses. Epidemiol Infect. 1996;117:113-119.
3. Rodríguez-Blanco I, Fernández LC, Suárez-Peñaranda JM, et al. Mycobacterium chelonae infection associated with tattoos. Acta Derm Venereol. 2011;91:61-62.
4. Karak K, Bhattacharyya S, Majumdar S, et al. Pulmonary infections caused by mycobacteria other than M. tuberculosis in and around Calcutta. Indian J Pathol Microbiol. 1996;39:131-134.
5. Butler WR, Floyd MM, Silcox V, et al. Standardized Method for HPLC Identification of Mycobacteria. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services; 1996.
6. Brown-Elliot BA, Wallace RJ Jr, Blinkhorn R, et al. Successful treatment of disseminated Mycobacterium chelonae infection with linezolid. Clin Infect Dis. 2001;33:1433-1434.
7. Brown BA, Wallace RJ Jr, Onyi GO, et al. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and Mycobacterium chelonae-like organisms. Antimicrob Agents Chemother. 1992;36:180-184.
8. Swenson JM, Wallace RJ Jr, Silcox VA, et al. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob Agents Chemother. 1985;28:807-811.
9. Leung YY, Choi KW, Ho KM, et al. Disseminated cutaneous infection with Mycobacterium chelonae mimicking panniculitis in a patient with dermatomyositis. Hong Kong Med J. 2005;11:515-519.
The Diagnosis: Mycobacterium chelonae Arising Within a Tattoo
A 3-mm punch biopsy specimen was obtained from one of the plaques. Histopathology revealed an unremarkable epidermis with granulomatous collections of epithelioid histiocytes in association with neutrophils and lymphocytes in the dermis (Figure 1). Periodic acid–Schiff stain was negative for fungal organisms. Gram stain was negative for bacteria. Fite stain was positive for acid-fast bacilli (Figure 2). Clinical and histopathologic findings led to the initial diagnosis of a mycobacterial infection within the tattoo. The patient was empirically started on oral doxycycline 100 mg twice daily and oral clarithromycin 500 mg twice daily with mild improvement of the lesions over the next month. After 6 weeks the mycobacterial cultures were persistently negative and high-performance liquid chromatography was performed verifying the presence of Mycobacterium chelonae. Clarithromycin was continued and the doxycycline was replaced with oral trimethoprim-sulfamethoxazole (double strength) twice daily due to resistance. The patient was referred to an infectious disease specialist who concurred with the treatment regimen for a duration of 6 months to a year. A chest radiograph also was performed to rule out disseminated disease. Several months later the patient’s close friend presented with a similar infection that was acquired on the same day as our patient at the same tattoo parlor. The New York City Department of Health and Mental Hygiene was notified about these cases and informed us of other cases in New York State linked to contaminated tattoo ink.
|
Mycobacterium chelonae is a rapidly growing nontuberculous mycobacteria (Runyon group IV) that is found in nature and contaminated sources such as soil, lakes, sewage, and tap water.1 Inoculation ofM chelonae through contaminated instruments leads to the formation of painful lesions, abscesses, fistulas, and granulomas that are extremely difficult to treat.2 In our patient, M chelonae was most likely transmitted via contaminated tap water that was used to dilute the black tattoo ink to yield a gray color. Alternative sources are the ink itself or the container used to mix the ink.3Mycobacterium chelonae can cause infections in the skin, lungs, joints, bones, and eyes.4 With the exception of lung disease, trauma is the usual inciting factor. Disseminated infections are almost exclusively found in immunosuppressed individuals. Mycobacterium chelonae is typically found to grow on culture within 7 days. However, in our case there was no growth after 6 weeks of incubation. High-performance liquid chromatography analysis of mycolic acid is an alternative method of identifying mycobacteria. This technique verified the presence of M chelonae in our case when cultures were persistently negative.5
Mycobacterium chelonae is difficult to treat. The most common antibiotics used for treatment are clarithromycin, azithromycin, doxycycline, and linezolid.6 Studies of various antibiotics have shown that clarithromycin is the most effective macrolide against M chelonae.7 Tetracyclines also were studied in their effectiveness at treating nontuberculous mycobacteria infections but were found to have increased resistance to M chelonae.8 Although treatment regimens vary, the highest success rates are achieved with a minimum of 6 months of therapy using at least 2 drugs. Longer treatment is recommended for immunocompromised individuals.9
The case we present is important from a public health perspective. The tattoo industry and ink manufacturers should bemade aware of the risks of various infections from nonsterile techniques. Tattoo parlor employees should be advised of the risks of using nonsterile water for ink dilution and cleaning tattoo equipment. They also should be continuously educated on aseptic techniques.
The Diagnosis: Mycobacterium chelonae Arising Within a Tattoo
A 3-mm punch biopsy specimen was obtained from one of the plaques. Histopathology revealed an unremarkable epidermis with granulomatous collections of epithelioid histiocytes in association with neutrophils and lymphocytes in the dermis (Figure 1). Periodic acid–Schiff stain was negative for fungal organisms. Gram stain was negative for bacteria. Fite stain was positive for acid-fast bacilli (Figure 2). Clinical and histopathologic findings led to the initial diagnosis of a mycobacterial infection within the tattoo. The patient was empirically started on oral doxycycline 100 mg twice daily and oral clarithromycin 500 mg twice daily with mild improvement of the lesions over the next month. After 6 weeks the mycobacterial cultures were persistently negative and high-performance liquid chromatography was performed verifying the presence of Mycobacterium chelonae. Clarithromycin was continued and the doxycycline was replaced with oral trimethoprim-sulfamethoxazole (double strength) twice daily due to resistance. The patient was referred to an infectious disease specialist who concurred with the treatment regimen for a duration of 6 months to a year. A chest radiograph also was performed to rule out disseminated disease. Several months later the patient’s close friend presented with a similar infection that was acquired on the same day as our patient at the same tattoo parlor. The New York City Department of Health and Mental Hygiene was notified about these cases and informed us of other cases in New York State linked to contaminated tattoo ink.
|
Mycobacterium chelonae is a rapidly growing nontuberculous mycobacteria (Runyon group IV) that is found in nature and contaminated sources such as soil, lakes, sewage, and tap water.1 Inoculation ofM chelonae through contaminated instruments leads to the formation of painful lesions, abscesses, fistulas, and granulomas that are extremely difficult to treat.2 In our patient, M chelonae was most likely transmitted via contaminated tap water that was used to dilute the black tattoo ink to yield a gray color. Alternative sources are the ink itself or the container used to mix the ink.3Mycobacterium chelonae can cause infections in the skin, lungs, joints, bones, and eyes.4 With the exception of lung disease, trauma is the usual inciting factor. Disseminated infections are almost exclusively found in immunosuppressed individuals. Mycobacterium chelonae is typically found to grow on culture within 7 days. However, in our case there was no growth after 6 weeks of incubation. High-performance liquid chromatography analysis of mycolic acid is an alternative method of identifying mycobacteria. This technique verified the presence of M chelonae in our case when cultures were persistently negative.5
Mycobacterium chelonae is difficult to treat. The most common antibiotics used for treatment are clarithromycin, azithromycin, doxycycline, and linezolid.6 Studies of various antibiotics have shown that clarithromycin is the most effective macrolide against M chelonae.7 Tetracyclines also were studied in their effectiveness at treating nontuberculous mycobacteria infections but were found to have increased resistance to M chelonae.8 Although treatment regimens vary, the highest success rates are achieved with a minimum of 6 months of therapy using at least 2 drugs. Longer treatment is recommended for immunocompromised individuals.9
The case we present is important from a public health perspective. The tattoo industry and ink manufacturers should bemade aware of the risks of various infections from nonsterile techniques. Tattoo parlor employees should be advised of the risks of using nonsterile water for ink dilution and cleaning tattoo equipment. They also should be continuously educated on aseptic techniques.
1. Lee RP, Cheung KW, Chiu KH, et al. Mycobacterium chelonae infection after total knee arthroplasty: a case report. J Orthop Surg (Hong Kong). 2012;20:134-136.
2. Camargo D, Saad C, Ruiz F, et al. latrogenic outbreak of M. chelonae skin abscesses. Epidemiol Infect. 1996;117:113-119.
3. Rodríguez-Blanco I, Fernández LC, Suárez-Peñaranda JM, et al. Mycobacterium chelonae infection associated with tattoos. Acta Derm Venereol. 2011;91:61-62.
4. Karak K, Bhattacharyya S, Majumdar S, et al. Pulmonary infections caused by mycobacteria other than M. tuberculosis in and around Calcutta. Indian J Pathol Microbiol. 1996;39:131-134.
5. Butler WR, Floyd MM, Silcox V, et al. Standardized Method for HPLC Identification of Mycobacteria. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services; 1996.
6. Brown-Elliot BA, Wallace RJ Jr, Blinkhorn R, et al. Successful treatment of disseminated Mycobacterium chelonae infection with linezolid. Clin Infect Dis. 2001;33:1433-1434.
7. Brown BA, Wallace RJ Jr, Onyi GO, et al. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and Mycobacterium chelonae-like organisms. Antimicrob Agents Chemother. 1992;36:180-184.
8. Swenson JM, Wallace RJ Jr, Silcox VA, et al. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob Agents Chemother. 1985;28:807-811.
9. Leung YY, Choi KW, Ho KM, et al. Disseminated cutaneous infection with Mycobacterium chelonae mimicking panniculitis in a patient with dermatomyositis. Hong Kong Med J. 2005;11:515-519.
1. Lee RP, Cheung KW, Chiu KH, et al. Mycobacterium chelonae infection after total knee arthroplasty: a case report. J Orthop Surg (Hong Kong). 2012;20:134-136.
2. Camargo D, Saad C, Ruiz F, et al. latrogenic outbreak of M. chelonae skin abscesses. Epidemiol Infect. 1996;117:113-119.
3. Rodríguez-Blanco I, Fernández LC, Suárez-Peñaranda JM, et al. Mycobacterium chelonae infection associated with tattoos. Acta Derm Venereol. 2011;91:61-62.
4. Karak K, Bhattacharyya S, Majumdar S, et al. Pulmonary infections caused by mycobacteria other than M. tuberculosis in and around Calcutta. Indian J Pathol Microbiol. 1996;39:131-134.
5. Butler WR, Floyd MM, Silcox V, et al. Standardized Method for HPLC Identification of Mycobacteria. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services; 1996.
6. Brown-Elliot BA, Wallace RJ Jr, Blinkhorn R, et al. Successful treatment of disseminated Mycobacterium chelonae infection with linezolid. Clin Infect Dis. 2001;33:1433-1434.
7. Brown BA, Wallace RJ Jr, Onyi GO, et al. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and Mycobacterium chelonae-like organisms. Antimicrob Agents Chemother. 1992;36:180-184.
8. Swenson JM, Wallace RJ Jr, Silcox VA, et al. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob Agents Chemother. 1985;28:807-811.
9. Leung YY, Choi KW, Ho KM, et al. Disseminated cutaneous infection with Mycobacterium chelonae mimicking panniculitis in a patient with dermatomyositis. Hong Kong Med J. 2005;11:515-519.
A 21-year-old man presented with growing, mildly pruritic, cutaneous papules and plaques on the right extensor forearm of 3 weeks’ duration. The lesions appeared 1 week after receiving a tattoo on the arm. One year prior the patient had a similar tattoo placed on another section of the right arm without any complications. The patient was afebrile and denied a history of sarcoidosis. Physical examination revealed indurated erythematous papules and plaques on the right extensor forearm that were most prominent in the gray-colored areas of the tattoo.
Papules on the Face and Body
The Diagnosis: Lichen Spinulosus
Lichen spinulosus, also referred to as keratosis spinulosa, is a disorder of keratinization characterized by grouped 1- to 3-mm papules with a horny spine localized to follicles (Figure).1 These lesions most commonly occur in the first through third decades of life, presenting as 2- to 6-cm patches on the neck, buttocks, thighs, abdomen, or extensor surfaces.1-4 Some patients report mild pruritus.1 The cause is unknown.1-3,5-7 Several proposed but unproven explanations include atopy,2,4 genetic predisposition,1,2 toxins,3,5 infection,5 abnormal immune response,8 and vitamin deficiency.1,6,7
Our patient’s presentation is atypical due to her age and the involvement of her face. Generalized lichen spinulosus in adults likely is rare. A few similar cases have been reported: a 61-year-old woman with Crohn disease and lichen spinulosus affecting the groin, inframammary region, and back8; 2 case reports linked to alcoholism-associated nutritional deficiency6,7; and generalized lichen spinulosus–like eruptions in 2 patients with human immuno-deficiency virus infection.9,10 Our patient’s medical history indicated an extensive smoking history; thiamine deficiency 5 years prior treated with vitamin B complex supplements, which she still takes; and a recent diagnosis of vitamin D deficiency. She had no evidence of immunodeficiency or systemic illness on routine screening.
The disorders of follicular keratinization are lichen spinulosus, keratosis pilaris, keratosis pilaris atrophicans, pityriasis rubra pilaris, lichen planopilaris, erythromelanosis follicularis faciei, and phrynoderma.11 The clinical differential diagnosis of lichen spinulosus includes keratosis pilaris, phrynoderma, pityriasis rubra pilaris, and frictional lichenoid eruption. Lichen spinulosus can be distinguished from keratosis pilaris by 4 factors1,11: (1) keratosis pilaris lesions develop slowly over time as opposed to the rapid onset in lichen spinulosus; (2) keratosis pilaris is preferentially located on the upper arms and legs; (3) keratosis pilaris does not develop in small clusters; (4) keratosis pilaris, unlike lichen spinulosus, often has a thin outline of perifollicular erythema. Histopathologically, lichen spinulosus is similar to keratosis pilaris, showing dilated hair follicles with a keratin plug and perifollicular and perivascular dermal lymphocytic infiltrate.1 A punch biopsy from our patient’s cheek demonstrated focal follicular hyperkeratosis with dermal perivascular inflammation. Periodic acid–Schiff with diastase stain was negative for pathogenic fungal organisms.
Treatment of lichen spinulosus is initiated to address cosmetic concerns. Traditionally, keratolytics and emollients are utilized. Success has been described with salicylic acid gel 6% without occlusion for 8 weeks12 or with occlusion for 2 weeks.13 Tar preparations and mid-potency topical corticosteroids may be used on lesions not located on the face.2,4,15 Topical vitamin A,2 lactic acid,4 and ammonium lactate lotion2 have been therapeutic in some cases. Facial lesions have been successfully treated with tacalcitol14 or tretinoin gel 0.04% in combination with hydroactive adhesive applications.15 In the case of lichen spinulosus accompanying alcoholism, oral vitamin supplementation has been sufficient for resolution.6,7
Our patient was initially prescribed ammonium lactate lotion twice daily and tretinoin cream 0.025% for facial application nightly. She only used the tretinoin briefly due to skin irritation, and she discontinued use of ammonium lactate due to lotion texture. Three months of vitamin A and vitamin B complex supplementation did not lead to any improvement. She believed the papules softened by scrubbing them with a loofah in the shower and then moisturizing. Malignancy workup, including a colonoscopy, mammography, chest radiograph, and basic blood tests, were negative. No remarkable change was noted by the patient at 1-year follow-up.
1. Friedman SJ. Lichen spinulosus. clinicopathologic review of thirty-five cases. J Am Acad Dermatol. 1990;22:261-264.
2. Boyd AS. Lichen spinulosus: case report and overview. Cutis. 1989;43:557-560.
3. Adamson H. Lichen pilaris, seu spinulosis. Br J Dermatol. 1905;17:39-54.
4. Strickling WA, Norton SA. Spiny eruption on the neck. diagnosis: lichen spinulosus (LS). Arch Dermatol. 2000;136:1165-1170.
5. Becker S. Lichen spinulosus following intradermal application of diphtheria toxin. Arch Dermatol Syph. 1930;21:839-840.
6. Irgang S. Lichen spinulosus responsive to ascorbic acid (vitamin C). case in an alcoholic adult. Skin. 1964;3:145-146.
7. Kabashima R, Sugita K, Kabashima K, et al. Lichen spinulosus in an alcoholic patient. Acta Derm Venereol. 2009;89:311-312.
8. Kano Y, Orihara M, Yagita A, et al. Lichen spinulosus in a patient with Crohn disease. Int J Dermatol. 1995;34:670-671.
9. Cohen SJ, Dicken CH. Generalized lichen spinulosus in an HIV-positive man. J Am Acad Dermatol. 1991;25:116-118.
10. Resnick SD, Murrell DF, Woosley J. Acne conglobata and a generalized lichen spinulosus-like eruption in a man seropositive for human immunodeficiency virus. J Am Acad Dermatol. 1992;26:1013-1014.
11. McMichael A, Curtis A, Guzman-Sanchez D, et al. Folliculitis and other follicular disorders. In: Bolognia J, Jorizzo J, Rapini R, eds. Dermatology. Vol 1. 3rd ed. New York, NY: Elsevier; 2012:571-586.
12. Tuyp E, McLeod WA, Boyko W. Lichen spinulosus with immunofluorescent studies. Cutis. 1984;33:197-200.
13. Maiocco KJ, Miller OF. Lichen spinulosus: response to therapy. Cutis. 1976;17:294-299.
14. Kim SH, Kang JH, Seo JK, et al. Successful treatment of lichen spinulosus with topical tacalcitol cream. Pediatr Dermatol. 2010;27:546-547.
15. Forman SB, Hudgins EM, Blaylock WK. Lichen spinulosus: excellent response to tretinoin gel and hydroactive adhesive applications. Arch Dermatol. 2007;143:122-123.
The Diagnosis: Lichen Spinulosus
Lichen spinulosus, also referred to as keratosis spinulosa, is a disorder of keratinization characterized by grouped 1- to 3-mm papules with a horny spine localized to follicles (Figure).1 These lesions most commonly occur in the first through third decades of life, presenting as 2- to 6-cm patches on the neck, buttocks, thighs, abdomen, or extensor surfaces.1-4 Some patients report mild pruritus.1 The cause is unknown.1-3,5-7 Several proposed but unproven explanations include atopy,2,4 genetic predisposition,1,2 toxins,3,5 infection,5 abnormal immune response,8 and vitamin deficiency.1,6,7
Our patient’s presentation is atypical due to her age and the involvement of her face. Generalized lichen spinulosus in adults likely is rare. A few similar cases have been reported: a 61-year-old woman with Crohn disease and lichen spinulosus affecting the groin, inframammary region, and back8; 2 case reports linked to alcoholism-associated nutritional deficiency6,7; and generalized lichen spinulosus–like eruptions in 2 patients with human immuno-deficiency virus infection.9,10 Our patient’s medical history indicated an extensive smoking history; thiamine deficiency 5 years prior treated with vitamin B complex supplements, which she still takes; and a recent diagnosis of vitamin D deficiency. She had no evidence of immunodeficiency or systemic illness on routine screening.
The disorders of follicular keratinization are lichen spinulosus, keratosis pilaris, keratosis pilaris atrophicans, pityriasis rubra pilaris, lichen planopilaris, erythromelanosis follicularis faciei, and phrynoderma.11 The clinical differential diagnosis of lichen spinulosus includes keratosis pilaris, phrynoderma, pityriasis rubra pilaris, and frictional lichenoid eruption. Lichen spinulosus can be distinguished from keratosis pilaris by 4 factors1,11: (1) keratosis pilaris lesions develop slowly over time as opposed to the rapid onset in lichen spinulosus; (2) keratosis pilaris is preferentially located on the upper arms and legs; (3) keratosis pilaris does not develop in small clusters; (4) keratosis pilaris, unlike lichen spinulosus, often has a thin outline of perifollicular erythema. Histopathologically, lichen spinulosus is similar to keratosis pilaris, showing dilated hair follicles with a keratin plug and perifollicular and perivascular dermal lymphocytic infiltrate.1 A punch biopsy from our patient’s cheek demonstrated focal follicular hyperkeratosis with dermal perivascular inflammation. Periodic acid–Schiff with diastase stain was negative for pathogenic fungal organisms.
Treatment of lichen spinulosus is initiated to address cosmetic concerns. Traditionally, keratolytics and emollients are utilized. Success has been described with salicylic acid gel 6% without occlusion for 8 weeks12 or with occlusion for 2 weeks.13 Tar preparations and mid-potency topical corticosteroids may be used on lesions not located on the face.2,4,15 Topical vitamin A,2 lactic acid,4 and ammonium lactate lotion2 have been therapeutic in some cases. Facial lesions have been successfully treated with tacalcitol14 or tretinoin gel 0.04% in combination with hydroactive adhesive applications.15 In the case of lichen spinulosus accompanying alcoholism, oral vitamin supplementation has been sufficient for resolution.6,7
Our patient was initially prescribed ammonium lactate lotion twice daily and tretinoin cream 0.025% for facial application nightly. She only used the tretinoin briefly due to skin irritation, and she discontinued use of ammonium lactate due to lotion texture. Three months of vitamin A and vitamin B complex supplementation did not lead to any improvement. She believed the papules softened by scrubbing them with a loofah in the shower and then moisturizing. Malignancy workup, including a colonoscopy, mammography, chest radiograph, and basic blood tests, were negative. No remarkable change was noted by the patient at 1-year follow-up.
The Diagnosis: Lichen Spinulosus
Lichen spinulosus, also referred to as keratosis spinulosa, is a disorder of keratinization characterized by grouped 1- to 3-mm papules with a horny spine localized to follicles (Figure).1 These lesions most commonly occur in the first through third decades of life, presenting as 2- to 6-cm patches on the neck, buttocks, thighs, abdomen, or extensor surfaces.1-4 Some patients report mild pruritus.1 The cause is unknown.1-3,5-7 Several proposed but unproven explanations include atopy,2,4 genetic predisposition,1,2 toxins,3,5 infection,5 abnormal immune response,8 and vitamin deficiency.1,6,7
Our patient’s presentation is atypical due to her age and the involvement of her face. Generalized lichen spinulosus in adults likely is rare. A few similar cases have been reported: a 61-year-old woman with Crohn disease and lichen spinulosus affecting the groin, inframammary region, and back8; 2 case reports linked to alcoholism-associated nutritional deficiency6,7; and generalized lichen spinulosus–like eruptions in 2 patients with human immuno-deficiency virus infection.9,10 Our patient’s medical history indicated an extensive smoking history; thiamine deficiency 5 years prior treated with vitamin B complex supplements, which she still takes; and a recent diagnosis of vitamin D deficiency. She had no evidence of immunodeficiency or systemic illness on routine screening.
The disorders of follicular keratinization are lichen spinulosus, keratosis pilaris, keratosis pilaris atrophicans, pityriasis rubra pilaris, lichen planopilaris, erythromelanosis follicularis faciei, and phrynoderma.11 The clinical differential diagnosis of lichen spinulosus includes keratosis pilaris, phrynoderma, pityriasis rubra pilaris, and frictional lichenoid eruption. Lichen spinulosus can be distinguished from keratosis pilaris by 4 factors1,11: (1) keratosis pilaris lesions develop slowly over time as opposed to the rapid onset in lichen spinulosus; (2) keratosis pilaris is preferentially located on the upper arms and legs; (3) keratosis pilaris does not develop in small clusters; (4) keratosis pilaris, unlike lichen spinulosus, often has a thin outline of perifollicular erythema. Histopathologically, lichen spinulosus is similar to keratosis pilaris, showing dilated hair follicles with a keratin plug and perifollicular and perivascular dermal lymphocytic infiltrate.1 A punch biopsy from our patient’s cheek demonstrated focal follicular hyperkeratosis with dermal perivascular inflammation. Periodic acid–Schiff with diastase stain was negative for pathogenic fungal organisms.
Treatment of lichen spinulosus is initiated to address cosmetic concerns. Traditionally, keratolytics and emollients are utilized. Success has been described with salicylic acid gel 6% without occlusion for 8 weeks12 or with occlusion for 2 weeks.13 Tar preparations and mid-potency topical corticosteroids may be used on lesions not located on the face.2,4,15 Topical vitamin A,2 lactic acid,4 and ammonium lactate lotion2 have been therapeutic in some cases. Facial lesions have been successfully treated with tacalcitol14 or tretinoin gel 0.04% in combination with hydroactive adhesive applications.15 In the case of lichen spinulosus accompanying alcoholism, oral vitamin supplementation has been sufficient for resolution.6,7
Our patient was initially prescribed ammonium lactate lotion twice daily and tretinoin cream 0.025% for facial application nightly. She only used the tretinoin briefly due to skin irritation, and she discontinued use of ammonium lactate due to lotion texture. Three months of vitamin A and vitamin B complex supplementation did not lead to any improvement. She believed the papules softened by scrubbing them with a loofah in the shower and then moisturizing. Malignancy workup, including a colonoscopy, mammography, chest radiograph, and basic blood tests, were negative. No remarkable change was noted by the patient at 1-year follow-up.
1. Friedman SJ. Lichen spinulosus. clinicopathologic review of thirty-five cases. J Am Acad Dermatol. 1990;22:261-264.
2. Boyd AS. Lichen spinulosus: case report and overview. Cutis. 1989;43:557-560.
3. Adamson H. Lichen pilaris, seu spinulosis. Br J Dermatol. 1905;17:39-54.
4. Strickling WA, Norton SA. Spiny eruption on the neck. diagnosis: lichen spinulosus (LS). Arch Dermatol. 2000;136:1165-1170.
5. Becker S. Lichen spinulosus following intradermal application of diphtheria toxin. Arch Dermatol Syph. 1930;21:839-840.
6. Irgang S. Lichen spinulosus responsive to ascorbic acid (vitamin C). case in an alcoholic adult. Skin. 1964;3:145-146.
7. Kabashima R, Sugita K, Kabashima K, et al. Lichen spinulosus in an alcoholic patient. Acta Derm Venereol. 2009;89:311-312.
8. Kano Y, Orihara M, Yagita A, et al. Lichen spinulosus in a patient with Crohn disease. Int J Dermatol. 1995;34:670-671.
9. Cohen SJ, Dicken CH. Generalized lichen spinulosus in an HIV-positive man. J Am Acad Dermatol. 1991;25:116-118.
10. Resnick SD, Murrell DF, Woosley J. Acne conglobata and a generalized lichen spinulosus-like eruption in a man seropositive for human immunodeficiency virus. J Am Acad Dermatol. 1992;26:1013-1014.
11. McMichael A, Curtis A, Guzman-Sanchez D, et al. Folliculitis and other follicular disorders. In: Bolognia J, Jorizzo J, Rapini R, eds. Dermatology. Vol 1. 3rd ed. New York, NY: Elsevier; 2012:571-586.
12. Tuyp E, McLeod WA, Boyko W. Lichen spinulosus with immunofluorescent studies. Cutis. 1984;33:197-200.
13. Maiocco KJ, Miller OF. Lichen spinulosus: response to therapy. Cutis. 1976;17:294-299.
14. Kim SH, Kang JH, Seo JK, et al. Successful treatment of lichen spinulosus with topical tacalcitol cream. Pediatr Dermatol. 2010;27:546-547.
15. Forman SB, Hudgins EM, Blaylock WK. Lichen spinulosus: excellent response to tretinoin gel and hydroactive adhesive applications. Arch Dermatol. 2007;143:122-123.
1. Friedman SJ. Lichen spinulosus. clinicopathologic review of thirty-five cases. J Am Acad Dermatol. 1990;22:261-264.
2. Boyd AS. Lichen spinulosus: case report and overview. Cutis. 1989;43:557-560.
3. Adamson H. Lichen pilaris, seu spinulosis. Br J Dermatol. 1905;17:39-54.
4. Strickling WA, Norton SA. Spiny eruption on the neck. diagnosis: lichen spinulosus (LS). Arch Dermatol. 2000;136:1165-1170.
5. Becker S. Lichen spinulosus following intradermal application of diphtheria toxin. Arch Dermatol Syph. 1930;21:839-840.
6. Irgang S. Lichen spinulosus responsive to ascorbic acid (vitamin C). case in an alcoholic adult. Skin. 1964;3:145-146.
7. Kabashima R, Sugita K, Kabashima K, et al. Lichen spinulosus in an alcoholic patient. Acta Derm Venereol. 2009;89:311-312.
8. Kano Y, Orihara M, Yagita A, et al. Lichen spinulosus in a patient with Crohn disease. Int J Dermatol. 1995;34:670-671.
9. Cohen SJ, Dicken CH. Generalized lichen spinulosus in an HIV-positive man. J Am Acad Dermatol. 1991;25:116-118.
10. Resnick SD, Murrell DF, Woosley J. Acne conglobata and a generalized lichen spinulosus-like eruption in a man seropositive for human immunodeficiency virus. J Am Acad Dermatol. 1992;26:1013-1014.
11. McMichael A, Curtis A, Guzman-Sanchez D, et al. Folliculitis and other follicular disorders. In: Bolognia J, Jorizzo J, Rapini R, eds. Dermatology. Vol 1. 3rd ed. New York, NY: Elsevier; 2012:571-586.
12. Tuyp E, McLeod WA, Boyko W. Lichen spinulosus with immunofluorescent studies. Cutis. 1984;33:197-200.
13. Maiocco KJ, Miller OF. Lichen spinulosus: response to therapy. Cutis. 1976;17:294-299.
14. Kim SH, Kang JH, Seo JK, et al. Successful treatment of lichen spinulosus with topical tacalcitol cream. Pediatr Dermatol. 2010;27:546-547.
15. Forman SB, Hudgins EM, Blaylock WK. Lichen spinulosus: excellent response to tretinoin gel and hydroactive adhesive applications. Arch Dermatol. 2007;143:122-123.
A 65-year-old woman presented for evaluation of papules on the face and body that had developed over a short period of time approximately 1.5 years prior. The papules were entirely asymptomatic. She had no prior treatment. On physical examination multiple flesh-colored papules with a central keratotic spicule were noted on the face, neck, arms, and legs.
Erythematous Friable Papule Under the Great Toenail
The Diagnosis: Subungual Eccrine Poroma
Histologic examination revealed a solitary papule (Figure 1). The epidermis was replaced with a well-defined proliferation of cuboidal and poroid cells. These cells demonstrated a downgrowth into the dermis in broad anastomosing bands that were surrounded by a fibrovascular stroma. Notably, there were few scattered foci of maturation into the ductal lumina of eccrine origin, which confirmed the diagnosis (Figure 2).
|
First described in 1956 by Goldman et al,1 eccrine poromas are benign, slow-growing tumors that account for approximately 10% of sweat gland neoplasms.2 Onset is typically in mid to late adulthood, and there is no ethnic or gender predilection. Classically, eccrine poromas present as soft, sessile, reddish papules or nodules measuring less than 2 cm that protrude from a well-circumscribed depression.
Although eccrine poromas can develop on hair-bearing regions, they most commonly arise on acral skin. In acral locations, bleeding, discharge, rapid growth, and localized pain can occur. These symptoms are even more common in this lesion’s malignant counterpart, eccrine porocarcinoma.3
Solar damage, radiation exposure, trauma, and human papillomavirus have been indicated in the pathogenesis of eccrine poroma; however, the exact etiology has yet to be defined.2,4 The differential diagnosis includes nevus, pyogenic granu-loma, acrochordon, basal cell carcinoma, and verruca vulgaris.5
Histologically, eccrine poromas consist of a combination of 5 distinct features: poroid cells, cuticular cells, intracytoplasmic or intercellular vacuolization en route to duct formation, massive necrosis or necrosis en masse, and nuclear monomorphism of the poroid and cuticular cells.6 However, all 5 histologic features do not have to be present for the diagnosis. Classically, there is a sharp demarcation of the lesion from the surrounding epidermis.7
Treatment of choice is complete excision to prevent recurrence and risk for malignant transformation in long-standing lesions. One study of eccrine porocarcinomas found that 18% (11/62) arose from a benign preexistent poroma.8 These malignant lesions are found more commonly on the extremities and tend to show a slight female predominance.9
Although there have been 2 reported cases of subungual eccrine porocarcinomas9,10 and 1 case of periungual eccrine porocarcinoma,11 according to an Ovid search using the terms porocarcinoma and nail, the benign subungual eccrine poroma is more rare.
1. Goldman P, Pinkus H, Rogin JR. Eccrine poroma; tumors exhibiting features of the epidermal sweat duct unit. AMA Arch Derm. 1956;74:511-521.
2. Orlandi C, Arcangeli F, Patrizi A, et al. Eccrine poroma in a child. Pediatr Dermatol. 2005;22:279-280.
3. Casper DJ, Glass LF, Shenefelt PD. An unusually large eccrine poroma: a case report and review of the literature. Cutis. 2011;88:227-229.
4. Kang MC, Kim SA, Lee KS, et al. A case of an unusual eccrine poroma on the left forearm area. Ann Dermatol. 2011;23:250-253.
5. Moore TO, Orman HL, Orman SK, et al. Poromas of the head and neck. J Am Acad Dermatol. 2001;44:48-52.
6. Chen CC, Chang YT, Liu HN. Clinical and histological characteristics of poroid neoplasms: a study of 25 cases in Taiwan. Int J Dermatol. 2006;45:722-727.
7. Smith EV, Madan V, Joshi A, et al. A pigmented lesion on the foot. Clin Exp Dermatol. 2012;37:84-86.
8. Robson A, Greene J, Ansari N, et al. Eccrine porocarcinoma (malignant eccrine poroma): a clinicopathologic study of 69 cases. Am J Surg Pathol. 2001;25:710-720.
9. Moussallem CD, Abi Hatem NE, El-Khoury ZN.Malignant porocarcinoma of the nail fold: a tricky diagnosis. Dermatol Online J. 2008;14:10.
10. Requena L, Sánchez M, Aguilar A, et al. Periungual porocarcinoma. Dermatologica. 1990;180:177-180.
11. van Gorp J, van der Putte SC. Periungual eccrine porocarcinoma. Dermatology. 1993;187:67-70.
The Diagnosis: Subungual Eccrine Poroma
Histologic examination revealed a solitary papule (Figure 1). The epidermis was replaced with a well-defined proliferation of cuboidal and poroid cells. These cells demonstrated a downgrowth into the dermis in broad anastomosing bands that were surrounded by a fibrovascular stroma. Notably, there were few scattered foci of maturation into the ductal lumina of eccrine origin, which confirmed the diagnosis (Figure 2).
|
First described in 1956 by Goldman et al,1 eccrine poromas are benign, slow-growing tumors that account for approximately 10% of sweat gland neoplasms.2 Onset is typically in mid to late adulthood, and there is no ethnic or gender predilection. Classically, eccrine poromas present as soft, sessile, reddish papules or nodules measuring less than 2 cm that protrude from a well-circumscribed depression.
Although eccrine poromas can develop on hair-bearing regions, they most commonly arise on acral skin. In acral locations, bleeding, discharge, rapid growth, and localized pain can occur. These symptoms are even more common in this lesion’s malignant counterpart, eccrine porocarcinoma.3
Solar damage, radiation exposure, trauma, and human papillomavirus have been indicated in the pathogenesis of eccrine poroma; however, the exact etiology has yet to be defined.2,4 The differential diagnosis includes nevus, pyogenic granu-loma, acrochordon, basal cell carcinoma, and verruca vulgaris.5
Histologically, eccrine poromas consist of a combination of 5 distinct features: poroid cells, cuticular cells, intracytoplasmic or intercellular vacuolization en route to duct formation, massive necrosis or necrosis en masse, and nuclear monomorphism of the poroid and cuticular cells.6 However, all 5 histologic features do not have to be present for the diagnosis. Classically, there is a sharp demarcation of the lesion from the surrounding epidermis.7
Treatment of choice is complete excision to prevent recurrence and risk for malignant transformation in long-standing lesions. One study of eccrine porocarcinomas found that 18% (11/62) arose from a benign preexistent poroma.8 These malignant lesions are found more commonly on the extremities and tend to show a slight female predominance.9
Although there have been 2 reported cases of subungual eccrine porocarcinomas9,10 and 1 case of periungual eccrine porocarcinoma,11 according to an Ovid search using the terms porocarcinoma and nail, the benign subungual eccrine poroma is more rare.
The Diagnosis: Subungual Eccrine Poroma
Histologic examination revealed a solitary papule (Figure 1). The epidermis was replaced with a well-defined proliferation of cuboidal and poroid cells. These cells demonstrated a downgrowth into the dermis in broad anastomosing bands that were surrounded by a fibrovascular stroma. Notably, there were few scattered foci of maturation into the ductal lumina of eccrine origin, which confirmed the diagnosis (Figure 2).
|
First described in 1956 by Goldman et al,1 eccrine poromas are benign, slow-growing tumors that account for approximately 10% of sweat gland neoplasms.2 Onset is typically in mid to late adulthood, and there is no ethnic or gender predilection. Classically, eccrine poromas present as soft, sessile, reddish papules or nodules measuring less than 2 cm that protrude from a well-circumscribed depression.
Although eccrine poromas can develop on hair-bearing regions, they most commonly arise on acral skin. In acral locations, bleeding, discharge, rapid growth, and localized pain can occur. These symptoms are even more common in this lesion’s malignant counterpart, eccrine porocarcinoma.3
Solar damage, radiation exposure, trauma, and human papillomavirus have been indicated in the pathogenesis of eccrine poroma; however, the exact etiology has yet to be defined.2,4 The differential diagnosis includes nevus, pyogenic granu-loma, acrochordon, basal cell carcinoma, and verruca vulgaris.5
Histologically, eccrine poromas consist of a combination of 5 distinct features: poroid cells, cuticular cells, intracytoplasmic or intercellular vacuolization en route to duct formation, massive necrosis or necrosis en masse, and nuclear monomorphism of the poroid and cuticular cells.6 However, all 5 histologic features do not have to be present for the diagnosis. Classically, there is a sharp demarcation of the lesion from the surrounding epidermis.7
Treatment of choice is complete excision to prevent recurrence and risk for malignant transformation in long-standing lesions. One study of eccrine porocarcinomas found that 18% (11/62) arose from a benign preexistent poroma.8 These malignant lesions are found more commonly on the extremities and tend to show a slight female predominance.9
Although there have been 2 reported cases of subungual eccrine porocarcinomas9,10 and 1 case of periungual eccrine porocarcinoma,11 according to an Ovid search using the terms porocarcinoma and nail, the benign subungual eccrine poroma is more rare.
1. Goldman P, Pinkus H, Rogin JR. Eccrine poroma; tumors exhibiting features of the epidermal sweat duct unit. AMA Arch Derm. 1956;74:511-521.
2. Orlandi C, Arcangeli F, Patrizi A, et al. Eccrine poroma in a child. Pediatr Dermatol. 2005;22:279-280.
3. Casper DJ, Glass LF, Shenefelt PD. An unusually large eccrine poroma: a case report and review of the literature. Cutis. 2011;88:227-229.
4. Kang MC, Kim SA, Lee KS, et al. A case of an unusual eccrine poroma on the left forearm area. Ann Dermatol. 2011;23:250-253.
5. Moore TO, Orman HL, Orman SK, et al. Poromas of the head and neck. J Am Acad Dermatol. 2001;44:48-52.
6. Chen CC, Chang YT, Liu HN. Clinical and histological characteristics of poroid neoplasms: a study of 25 cases in Taiwan. Int J Dermatol. 2006;45:722-727.
7. Smith EV, Madan V, Joshi A, et al. A pigmented lesion on the foot. Clin Exp Dermatol. 2012;37:84-86.
8. Robson A, Greene J, Ansari N, et al. Eccrine porocarcinoma (malignant eccrine poroma): a clinicopathologic study of 69 cases. Am J Surg Pathol. 2001;25:710-720.
9. Moussallem CD, Abi Hatem NE, El-Khoury ZN.Malignant porocarcinoma of the nail fold: a tricky diagnosis. Dermatol Online J. 2008;14:10.
10. Requena L, Sánchez M, Aguilar A, et al. Periungual porocarcinoma. Dermatologica. 1990;180:177-180.
11. van Gorp J, van der Putte SC. Periungual eccrine porocarcinoma. Dermatology. 1993;187:67-70.
1. Goldman P, Pinkus H, Rogin JR. Eccrine poroma; tumors exhibiting features of the epidermal sweat duct unit. AMA Arch Derm. 1956;74:511-521.
2. Orlandi C, Arcangeli F, Patrizi A, et al. Eccrine poroma in a child. Pediatr Dermatol. 2005;22:279-280.
3. Casper DJ, Glass LF, Shenefelt PD. An unusually large eccrine poroma: a case report and review of the literature. Cutis. 2011;88:227-229.
4. Kang MC, Kim SA, Lee KS, et al. A case of an unusual eccrine poroma on the left forearm area. Ann Dermatol. 2011;23:250-253.
5. Moore TO, Orman HL, Orman SK, et al. Poromas of the head and neck. J Am Acad Dermatol. 2001;44:48-52.
6. Chen CC, Chang YT, Liu HN. Clinical and histological characteristics of poroid neoplasms: a study of 25 cases in Taiwan. Int J Dermatol. 2006;45:722-727.
7. Smith EV, Madan V, Joshi A, et al. A pigmented lesion on the foot. Clin Exp Dermatol. 2012;37:84-86.
8. Robson A, Greene J, Ansari N, et al. Eccrine porocarcinoma (malignant eccrine poroma): a clinicopathologic study of 69 cases. Am J Surg Pathol. 2001;25:710-720.
9. Moussallem CD, Abi Hatem NE, El-Khoury ZN.Malignant porocarcinoma of the nail fold: a tricky diagnosis. Dermatol Online J. 2008;14:10.
10. Requena L, Sánchez M, Aguilar A, et al. Periungual porocarcinoma. Dermatologica. 1990;180:177-180.
11. van Gorp J, van der Putte SC. Periungual eccrine porocarcinoma. Dermatology. 1993;187:67-70.
A 20-year-old woman presented with a subungual growth of 1 year’s duration that would intermittently bleed. Despite treatment with silver nitrate in 2 sequential treatments, the lesion continued to increase in size. Physical examination revealed a 6×7-mm erythematous, friable, well-defined papule under the medial aspect of the distal great toenail. Complete surgical excision of the lesion was performed.
What Is Your Diagnosis? Pemphigoid Gestationis (Herpes Gestationis)
A 37-year-old pregnant woman at 25 weeks’ gestation presented with a generalized pruritic rash of 3 weeks’ duration. The rash had initiated around the umbilicus and continued to progress with subsequent involvement of the arms and legs. The patient reported no allergies or current medications, and her personal and family history was unremarkable. She had 2 prior uncomplicated pregnancies and deliveries. Physical examination revealed severe ecchymotic plaques, vesicles, and bullae on the arms (top), as well as confluent erythematous plaques on the abdomen (bottom), back, and legs. The mucosal surfaces, face, palms, and soles were spared. Laboratory values were within reference range.
The Diagnosis: Pemphigoid Gestationis (Herpes Gestationis)
Dermoscopy revealed a patch of erythema with early central vesiculation (Figure 1). Perilesional skin biopsies revealed subepidermal bullae, and direct immunofluorescence revealed linear C3 and IgG deposition at the dermoepidermal junction (Figure 2).
|
Dermatoses of pregnancy are uncommon and may demonstrate similar clinical manifestations. Pemphigoid gestationis (herpes gestationis) is a condition that may initially mimic other pregnancy-related skin diseases but is followed by the classic manifestations of a bullous disease. A biopsy specimen is needed to identify the epidermal lesions that are present. Once identified, it responds to treatment with steroids.
Pemphigoid gestationis is a skin disorder in which circulating IgG autoantibodies react against transmembrane proteins and hemidesmosomal components of the epidermal basal cells.1 This process leads to complement protein activation through the classical pathway, which promotes leukocyte recruitment and degranulation. The initial clinical manifestation includes pruritus, which is followed by characteristic bullous lesions.
Pemphigoid gestationis is hypothesized to arise from pathologic maternal IgG induced by paternal HLA antigens found in the placenta.2 The incidence of pemphigoid gestationis is thought to range from 1:10,000 to 1:50,000,3 with typical presentation in the second or third trimesters. It may be exacerbated during delivery and generally resolves after delivery. The periumbilical region is the first site affected with subsequent spreading to the arms and legs.3 The initial differential diagnosis based on patient history can include an adverse drug reaction or pruritic urticarial papules and pustules of pregnancy. Diagnosis is based on histologic examination of a perilesional skin biopsy. Light microscopy of the biopsy typically reveals subepidermal bullae with a predominance of infiltrated eosinophils. Direct immunofluorescence of the biopsy specimen usually confirms the diagnosis with the presence of linear C3 and IgG deposition at the dermoepidermal junction. Indirect immunofluorescence occasionally may reveal IgG deposition in the basal membrane.4
Treatment generally includes the use of topical and oral steroids.2,5 Fetal risks associated with the disease include premature birth and low birth weight.2,3 Our patient initially was started on a 1-mg/kg dose of oral prednisone and topical steroid (prednisone 60 mg in a tapering dose every 5 days); she showed a good response at 1-week follow-up. She was well controlled with a lower maintenance dose through the rest of the pregnancy and did not show subsequent disease exacerbation.
1. Parker SR, MacKelfresh J. Autoimmune blistering disease in the elderly. Clin Dermatol. 2011;29:69-79.
2. Shornick JK. Dermatoses of pregnancy. Semin Cutan Med Surg. 1998;17:172-181.
3. Al-Fouzan AW, Galadari I, Oumeish I, et al. Herpes gestationis (pemphigoid gestationis). Clin Dermatol. 2006;24:109-112.
4. Imber MJ, Murphy GF, Jordon RE. The immunopathology of bullous pemphigoid. Clin Dermatol. 1987;5:81-92.
5. Kirtschig G, Middleton P, Bennett C, et al. Interventions for bullous pemphigoid. Cochrane Database Syst Rev. 2010:CD002292.
A 37-year-old pregnant woman at 25 weeks’ gestation presented with a generalized pruritic rash of 3 weeks’ duration. The rash had initiated around the umbilicus and continued to progress with subsequent involvement of the arms and legs. The patient reported no allergies or current medications, and her personal and family history was unremarkable. She had 2 prior uncomplicated pregnancies and deliveries. Physical examination revealed severe ecchymotic plaques, vesicles, and bullae on the arms (top), as well as confluent erythematous plaques on the abdomen (bottom), back, and legs. The mucosal surfaces, face, palms, and soles were spared. Laboratory values were within reference range.
The Diagnosis: Pemphigoid Gestationis (Herpes Gestationis)
Dermoscopy revealed a patch of erythema with early central vesiculation (Figure 1). Perilesional skin biopsies revealed subepidermal bullae, and direct immunofluorescence revealed linear C3 and IgG deposition at the dermoepidermal junction (Figure 2).
|
Dermatoses of pregnancy are uncommon and may demonstrate similar clinical manifestations. Pemphigoid gestationis (herpes gestationis) is a condition that may initially mimic other pregnancy-related skin diseases but is followed by the classic manifestations of a bullous disease. A biopsy specimen is needed to identify the epidermal lesions that are present. Once identified, it responds to treatment with steroids.
Pemphigoid gestationis is a skin disorder in which circulating IgG autoantibodies react against transmembrane proteins and hemidesmosomal components of the epidermal basal cells.1 This process leads to complement protein activation through the classical pathway, which promotes leukocyte recruitment and degranulation. The initial clinical manifestation includes pruritus, which is followed by characteristic bullous lesions.
Pemphigoid gestationis is hypothesized to arise from pathologic maternal IgG induced by paternal HLA antigens found in the placenta.2 The incidence of pemphigoid gestationis is thought to range from 1:10,000 to 1:50,000,3 with typical presentation in the second or third trimesters. It may be exacerbated during delivery and generally resolves after delivery. The periumbilical region is the first site affected with subsequent spreading to the arms and legs.3 The initial differential diagnosis based on patient history can include an adverse drug reaction or pruritic urticarial papules and pustules of pregnancy. Diagnosis is based on histologic examination of a perilesional skin biopsy. Light microscopy of the biopsy typically reveals subepidermal bullae with a predominance of infiltrated eosinophils. Direct immunofluorescence of the biopsy specimen usually confirms the diagnosis with the presence of linear C3 and IgG deposition at the dermoepidermal junction. Indirect immunofluorescence occasionally may reveal IgG deposition in the basal membrane.4
Treatment generally includes the use of topical and oral steroids.2,5 Fetal risks associated with the disease include premature birth and low birth weight.2,3 Our patient initially was started on a 1-mg/kg dose of oral prednisone and topical steroid (prednisone 60 mg in a tapering dose every 5 days); she showed a good response at 1-week follow-up. She was well controlled with a lower maintenance dose through the rest of the pregnancy and did not show subsequent disease exacerbation.
A 37-year-old pregnant woman at 25 weeks’ gestation presented with a generalized pruritic rash of 3 weeks’ duration. The rash had initiated around the umbilicus and continued to progress with subsequent involvement of the arms and legs. The patient reported no allergies or current medications, and her personal and family history was unremarkable. She had 2 prior uncomplicated pregnancies and deliveries. Physical examination revealed severe ecchymotic plaques, vesicles, and bullae on the arms (top), as well as confluent erythematous plaques on the abdomen (bottom), back, and legs. The mucosal surfaces, face, palms, and soles were spared. Laboratory values were within reference range.
The Diagnosis: Pemphigoid Gestationis (Herpes Gestationis)
Dermoscopy revealed a patch of erythema with early central vesiculation (Figure 1). Perilesional skin biopsies revealed subepidermal bullae, and direct immunofluorescence revealed linear C3 and IgG deposition at the dermoepidermal junction (Figure 2).
|
Dermatoses of pregnancy are uncommon and may demonstrate similar clinical manifestations. Pemphigoid gestationis (herpes gestationis) is a condition that may initially mimic other pregnancy-related skin diseases but is followed by the classic manifestations of a bullous disease. A biopsy specimen is needed to identify the epidermal lesions that are present. Once identified, it responds to treatment with steroids.
Pemphigoid gestationis is a skin disorder in which circulating IgG autoantibodies react against transmembrane proteins and hemidesmosomal components of the epidermal basal cells.1 This process leads to complement protein activation through the classical pathway, which promotes leukocyte recruitment and degranulation. The initial clinical manifestation includes pruritus, which is followed by characteristic bullous lesions.
Pemphigoid gestationis is hypothesized to arise from pathologic maternal IgG induced by paternal HLA antigens found in the placenta.2 The incidence of pemphigoid gestationis is thought to range from 1:10,000 to 1:50,000,3 with typical presentation in the second or third trimesters. It may be exacerbated during delivery and generally resolves after delivery. The periumbilical region is the first site affected with subsequent spreading to the arms and legs.3 The initial differential diagnosis based on patient history can include an adverse drug reaction or pruritic urticarial papules and pustules of pregnancy. Diagnosis is based on histologic examination of a perilesional skin biopsy. Light microscopy of the biopsy typically reveals subepidermal bullae with a predominance of infiltrated eosinophils. Direct immunofluorescence of the biopsy specimen usually confirms the diagnosis with the presence of linear C3 and IgG deposition at the dermoepidermal junction. Indirect immunofluorescence occasionally may reveal IgG deposition in the basal membrane.4
Treatment generally includes the use of topical and oral steroids.2,5 Fetal risks associated with the disease include premature birth and low birth weight.2,3 Our patient initially was started on a 1-mg/kg dose of oral prednisone and topical steroid (prednisone 60 mg in a tapering dose every 5 days); she showed a good response at 1-week follow-up. She was well controlled with a lower maintenance dose through the rest of the pregnancy and did not show subsequent disease exacerbation.
1. Parker SR, MacKelfresh J. Autoimmune blistering disease in the elderly. Clin Dermatol. 2011;29:69-79.
2. Shornick JK. Dermatoses of pregnancy. Semin Cutan Med Surg. 1998;17:172-181.
3. Al-Fouzan AW, Galadari I, Oumeish I, et al. Herpes gestationis (pemphigoid gestationis). Clin Dermatol. 2006;24:109-112.
4. Imber MJ, Murphy GF, Jordon RE. The immunopathology of bullous pemphigoid. Clin Dermatol. 1987;5:81-92.
5. Kirtschig G, Middleton P, Bennett C, et al. Interventions for bullous pemphigoid. Cochrane Database Syst Rev. 2010:CD002292.
1. Parker SR, MacKelfresh J. Autoimmune blistering disease in the elderly. Clin Dermatol. 2011;29:69-79.
2. Shornick JK. Dermatoses of pregnancy. Semin Cutan Med Surg. 1998;17:172-181.
3. Al-Fouzan AW, Galadari I, Oumeish I, et al. Herpes gestationis (pemphigoid gestationis). Clin Dermatol. 2006;24:109-112.
4. Imber MJ, Murphy GF, Jordon RE. The immunopathology of bullous pemphigoid. Clin Dermatol. 1987;5:81-92.
5. Kirtschig G, Middleton P, Bennett C, et al. Interventions for bullous pemphigoid. Cochrane Database Syst Rev. 2010:CD002292.
Dreadlocks
The Diagnosis: “Pseudonits”
Dreadlocks are matted hairs formed into thick ropelike strands (Figure 1). As a chosen hairstyle dreadlocks are worn by individuals of many different ethnic groups but are most commonly associated with members of the Rastafarian movement, or Rastas. Various techniques are used to form dreadlocks including backcombing (also known as teasing) in which the hair is combed toward the scalp to facilitate tangles and knotting or the neglect method in which the hair is not combed, brushed, or cut, becoming tangled and twisted as it grows long. Manicuring and perming techniques may be used to create the starting point for dreadlocks.
Telogen hairs are the hairs shed as part of normal hair cycling. The average person is estimated to lose 50 telogen hairs per day.1 With dreadlocks, the hairs are entangled distally, so when telogen hairs are released from scalp follicles, the shed hairs remain part of the locks. These “club” hairs have a bulbous white tip situated at the proximal end of the hair shaft (Figure 2) and should not be mistaken for the eggs of Pediculus humanus var capitis, hence the designation pseudonits.2 Hair casts, keratinous material surrounding the hair shafts when there is infundibular or perifollicular hyperkeratosis, also may resemble nits.3 Hair cast pseudonits can be distinguished from true nits by one’s ability to slide the hair casts freely along the hair shaft, whereas lice ova are cemented to the hair shaft and fixed in place.
Figure 2. “Club” hairs with a bulbous white tip situated at the
proximal end of the hair shaft (“pseudonits”).
1. Sperling LC. An Atlas of Hair Pathology with Clinical Correlations. New York, NY: The Parthenon Publishing Group; 2003.
2. Salih S, Bowling JC. Pseudonits in dreadlocked hair: A louse-y case of nits. Dermatology. 2006;213:245.
3. Lam M, Crutchfield CE 3rd, Lewis EJ. Hair casts: a case of pseudonits. Cutis. 1997;60:251-252.
The Diagnosis: “Pseudonits”
Dreadlocks are matted hairs formed into thick ropelike strands (Figure 1). As a chosen hairstyle dreadlocks are worn by individuals of many different ethnic groups but are most commonly associated with members of the Rastafarian movement, or Rastas. Various techniques are used to form dreadlocks including backcombing (also known as teasing) in which the hair is combed toward the scalp to facilitate tangles and knotting or the neglect method in which the hair is not combed, brushed, or cut, becoming tangled and twisted as it grows long. Manicuring and perming techniques may be used to create the starting point for dreadlocks.
Telogen hairs are the hairs shed as part of normal hair cycling. The average person is estimated to lose 50 telogen hairs per day.1 With dreadlocks, the hairs are entangled distally, so when telogen hairs are released from scalp follicles, the shed hairs remain part of the locks. These “club” hairs have a bulbous white tip situated at the proximal end of the hair shaft (Figure 2) and should not be mistaken for the eggs of Pediculus humanus var capitis, hence the designation pseudonits.2 Hair casts, keratinous material surrounding the hair shafts when there is infundibular or perifollicular hyperkeratosis, also may resemble nits.3 Hair cast pseudonits can be distinguished from true nits by one’s ability to slide the hair casts freely along the hair shaft, whereas lice ova are cemented to the hair shaft and fixed in place.
Figure 2. “Club” hairs with a bulbous white tip situated at the
proximal end of the hair shaft (“pseudonits”).
The Diagnosis: “Pseudonits”
Dreadlocks are matted hairs formed into thick ropelike strands (Figure 1). As a chosen hairstyle dreadlocks are worn by individuals of many different ethnic groups but are most commonly associated with members of the Rastafarian movement, or Rastas. Various techniques are used to form dreadlocks including backcombing (also known as teasing) in which the hair is combed toward the scalp to facilitate tangles and knotting or the neglect method in which the hair is not combed, brushed, or cut, becoming tangled and twisted as it grows long. Manicuring and perming techniques may be used to create the starting point for dreadlocks.
Telogen hairs are the hairs shed as part of normal hair cycling. The average person is estimated to lose 50 telogen hairs per day.1 With dreadlocks, the hairs are entangled distally, so when telogen hairs are released from scalp follicles, the shed hairs remain part of the locks. These “club” hairs have a bulbous white tip situated at the proximal end of the hair shaft (Figure 2) and should not be mistaken for the eggs of Pediculus humanus var capitis, hence the designation pseudonits.2 Hair casts, keratinous material surrounding the hair shafts when there is infundibular or perifollicular hyperkeratosis, also may resemble nits.3 Hair cast pseudonits can be distinguished from true nits by one’s ability to slide the hair casts freely along the hair shaft, whereas lice ova are cemented to the hair shaft and fixed in place.
Figure 2. “Club” hairs with a bulbous white tip situated at the
proximal end of the hair shaft (“pseudonits”).
1. Sperling LC. An Atlas of Hair Pathology with Clinical Correlations. New York, NY: The Parthenon Publishing Group; 2003.
2. Salih S, Bowling JC. Pseudonits in dreadlocked hair: A louse-y case of nits. Dermatology. 2006;213:245.
3. Lam M, Crutchfield CE 3rd, Lewis EJ. Hair casts: a case of pseudonits. Cutis. 1997;60:251-252.
1. Sperling LC. An Atlas of Hair Pathology with Clinical Correlations. New York, NY: The Parthenon Publishing Group; 2003.
2. Salih S, Bowling JC. Pseudonits in dreadlocked hair: A louse-y case of nits. Dermatology. 2006;213:245.
3. Lam M, Crutchfield CE 3rd, Lewis EJ. Hair casts: a case of pseudonits. Cutis. 1997;60:251-252.
A 17-year-old adolescent girl presented to our dermatology office with dreadlocks that were unrelated to the reason for her visit. She had mild scalp pruritus. Close inspection of the hair and scalp was performed.
Nodule on the Second Toe in an Infant
The Diagnosis: Infantile Digital Fibromatosis
On examination, the patient appeared well developed, well nourished, and had a 1×0.5-cm, flesh-colored, firm, nontender nodule on the dorsolateral aspect of the left second toe. After excision by a pediatric surgeon, the specimen was submitted for histopathologic examination. Dense bands of collagen with spindled myofibroblasts containing characteristic eosinophilic cytoplasmic inclusion bodies staining with phosphotungstic acid hematoxylin confirmed the diagnosis of infantile digital fibromatosis (Figure). Postoperatively the patient did well with normal healing and no complications. After 4 months, a recurrence was noted and the parents were considering reexcision.
|
Infantile digital fibromatosis is a rare, benign, often spontaneously regressing, fibrous tissue tumor of infancy and childhood.1 The prevalence of this tumor is unknown. It can be present at birth or more commonly appears in the first year of life. The lesions present as 1- to 2-cm, firm, flesh-colored nodules that initially grow slowly but have the potential for rapid growth in subsequent months. They occur preferentially on the extensor aspects of the digits, typically sparing the thumb and great toe.1 The clinical differential diagnosis includes keloids or hypertrophic scars, granuloma annulare, sarcoidosis, acral fibrokeratomas, periungual fibromas, supernumerary digits, pachydermodactyly, juvenile aponeurotic fibroma, and terminal osseous dysplasia and pigmentary defects.2
The histology of infantile digital fibromatosis is distinctive. Spindled myofibroblasts that contain round or ovoid, eosinophilic, cytoplasmic inclusion bodies composed of an accumulation of actin and vimentin filaments are characteristic.1 Inclusions are typically juxtanuclear and may indent the adjacent nucleus. The inclusion bodies stain red with Masson trichrome stain and purple with phosphotungstic acid hematoxylin stain.1 The histopathologic differential diagnosis includes scar, angiofibroma, dermatofibroma, neurofibroma, and angiofibromatous verruca vulgaris.
Although many treatments exist for infantile digital fibromatosis, optimal therapy is not standardized. Most lesions spontaneously regress, but func-tional disability with deforming contractures can occur if untreated. Topical therapy with imiquimod cream 5% and diflucortolone valerate cream have been reported to produce no effect on tumor size.3 Intralesional 5-fluorouracil was successful in treating a patient after 5 monthly injections.4 Intralesional triamcinolone 10 mg/cc injections were shown to be a well-tolerated and successful treatment in a case series of 7 patients.5 The most utilized intervention appears to be standard surgery, with a few patients treated with Mohs micrographic surgery.6,7
Treatment with surgical excision often results in recurrence, with studies showing a 50% to 75% recurrence rate.8,9 Our case is not atypical and illustrates this phenomenon. Other reported complications of surgical management include hypertrophic scarring and reduced distal interphalangeal joint mobility.5 Unless infantile digital fibromatosis causes mobility dysfunction or related disabilities, observation with regular follow-up should be considered, as lesions can spontaneously regress.
1. Heymann WR. Infantile digital fibromatosis. J Am Acad Dermatol. 2008;59:122-123.
2. Niamba P, Léauté-Labrèze C, Boralevi F, et al. Further documentation of spontaneous regression of infantile digital fibromatosis. Pediatr Dermatol. 2007;24:280-284.
3. Failla V, Wauters O, Nikkels-Tassoudji N, et al. Congenital infantile digital fibromatosis: a case report and review of the literature. Rare Tumors. 2009;1:e47.
4. Oh CK, Son HS, Kwon YW, et al. Intralesional fluorouracil injection in infantile digital fibromatosis. Arch Dermatol. 2005;141:549-550
5. Holmes WJ, Mishra A, McArthur P. Intra-lesional steroid for the management of symptomatic infantile digital fibromatosis. J Plast Reconstr Aesthet Surg. 2011;64:632-637.
6. Campbell LB, Petrick MG. Mohs micrographic surgery for a problematic infantile digital fibroma. Dermatol Surg. 2007;33:385-387.
7. Albertini JG, Welsch MJ, Conger LA, et al. Infantile digital fibroma treated with Mohs micrographic surgery. Dermatol Surg. 2002;28:959-961.
8. Kang SK, Chang SE, Choi JH, et al. A case of congenital infantile digital fibromatosis. Pediatr Dermatol. 2002;19:462-463.
9. Rimareix F, Bardot J, Andrac L, et al. Infantile digital fibroma—report on eleven cases. Eur J Pediatr Surg. 1997;7:345-348.
The Diagnosis: Infantile Digital Fibromatosis
On examination, the patient appeared well developed, well nourished, and had a 1×0.5-cm, flesh-colored, firm, nontender nodule on the dorsolateral aspect of the left second toe. After excision by a pediatric surgeon, the specimen was submitted for histopathologic examination. Dense bands of collagen with spindled myofibroblasts containing characteristic eosinophilic cytoplasmic inclusion bodies staining with phosphotungstic acid hematoxylin confirmed the diagnosis of infantile digital fibromatosis (Figure). Postoperatively the patient did well with normal healing and no complications. After 4 months, a recurrence was noted and the parents were considering reexcision.
|
Infantile digital fibromatosis is a rare, benign, often spontaneously regressing, fibrous tissue tumor of infancy and childhood.1 The prevalence of this tumor is unknown. It can be present at birth or more commonly appears in the first year of life. The lesions present as 1- to 2-cm, firm, flesh-colored nodules that initially grow slowly but have the potential for rapid growth in subsequent months. They occur preferentially on the extensor aspects of the digits, typically sparing the thumb and great toe.1 The clinical differential diagnosis includes keloids or hypertrophic scars, granuloma annulare, sarcoidosis, acral fibrokeratomas, periungual fibromas, supernumerary digits, pachydermodactyly, juvenile aponeurotic fibroma, and terminal osseous dysplasia and pigmentary defects.2
The histology of infantile digital fibromatosis is distinctive. Spindled myofibroblasts that contain round or ovoid, eosinophilic, cytoplasmic inclusion bodies composed of an accumulation of actin and vimentin filaments are characteristic.1 Inclusions are typically juxtanuclear and may indent the adjacent nucleus. The inclusion bodies stain red with Masson trichrome stain and purple with phosphotungstic acid hematoxylin stain.1 The histopathologic differential diagnosis includes scar, angiofibroma, dermatofibroma, neurofibroma, and angiofibromatous verruca vulgaris.
Although many treatments exist for infantile digital fibromatosis, optimal therapy is not standardized. Most lesions spontaneously regress, but func-tional disability with deforming contractures can occur if untreated. Topical therapy with imiquimod cream 5% and diflucortolone valerate cream have been reported to produce no effect on tumor size.3 Intralesional 5-fluorouracil was successful in treating a patient after 5 monthly injections.4 Intralesional triamcinolone 10 mg/cc injections were shown to be a well-tolerated and successful treatment in a case series of 7 patients.5 The most utilized intervention appears to be standard surgery, with a few patients treated with Mohs micrographic surgery.6,7
Treatment with surgical excision often results in recurrence, with studies showing a 50% to 75% recurrence rate.8,9 Our case is not atypical and illustrates this phenomenon. Other reported complications of surgical management include hypertrophic scarring and reduced distal interphalangeal joint mobility.5 Unless infantile digital fibromatosis causes mobility dysfunction or related disabilities, observation with regular follow-up should be considered, as lesions can spontaneously regress.
The Diagnosis: Infantile Digital Fibromatosis
On examination, the patient appeared well developed, well nourished, and had a 1×0.5-cm, flesh-colored, firm, nontender nodule on the dorsolateral aspect of the left second toe. After excision by a pediatric surgeon, the specimen was submitted for histopathologic examination. Dense bands of collagen with spindled myofibroblasts containing characteristic eosinophilic cytoplasmic inclusion bodies staining with phosphotungstic acid hematoxylin confirmed the diagnosis of infantile digital fibromatosis (Figure). Postoperatively the patient did well with normal healing and no complications. After 4 months, a recurrence was noted and the parents were considering reexcision.
|
Infantile digital fibromatosis is a rare, benign, often spontaneously regressing, fibrous tissue tumor of infancy and childhood.1 The prevalence of this tumor is unknown. It can be present at birth or more commonly appears in the first year of life. The lesions present as 1- to 2-cm, firm, flesh-colored nodules that initially grow slowly but have the potential for rapid growth in subsequent months. They occur preferentially on the extensor aspects of the digits, typically sparing the thumb and great toe.1 The clinical differential diagnosis includes keloids or hypertrophic scars, granuloma annulare, sarcoidosis, acral fibrokeratomas, periungual fibromas, supernumerary digits, pachydermodactyly, juvenile aponeurotic fibroma, and terminal osseous dysplasia and pigmentary defects.2
The histology of infantile digital fibromatosis is distinctive. Spindled myofibroblasts that contain round or ovoid, eosinophilic, cytoplasmic inclusion bodies composed of an accumulation of actin and vimentin filaments are characteristic.1 Inclusions are typically juxtanuclear and may indent the adjacent nucleus. The inclusion bodies stain red with Masson trichrome stain and purple with phosphotungstic acid hematoxylin stain.1 The histopathologic differential diagnosis includes scar, angiofibroma, dermatofibroma, neurofibroma, and angiofibromatous verruca vulgaris.
Although many treatments exist for infantile digital fibromatosis, optimal therapy is not standardized. Most lesions spontaneously regress, but func-tional disability with deforming contractures can occur if untreated. Topical therapy with imiquimod cream 5% and diflucortolone valerate cream have been reported to produce no effect on tumor size.3 Intralesional 5-fluorouracil was successful in treating a patient after 5 monthly injections.4 Intralesional triamcinolone 10 mg/cc injections were shown to be a well-tolerated and successful treatment in a case series of 7 patients.5 The most utilized intervention appears to be standard surgery, with a few patients treated with Mohs micrographic surgery.6,7
Treatment with surgical excision often results in recurrence, with studies showing a 50% to 75% recurrence rate.8,9 Our case is not atypical and illustrates this phenomenon. Other reported complications of surgical management include hypertrophic scarring and reduced distal interphalangeal joint mobility.5 Unless infantile digital fibromatosis causes mobility dysfunction or related disabilities, observation with regular follow-up should be considered, as lesions can spontaneously regress.
1. Heymann WR. Infantile digital fibromatosis. J Am Acad Dermatol. 2008;59:122-123.
2. Niamba P, Léauté-Labrèze C, Boralevi F, et al. Further documentation of spontaneous regression of infantile digital fibromatosis. Pediatr Dermatol. 2007;24:280-284.
3. Failla V, Wauters O, Nikkels-Tassoudji N, et al. Congenital infantile digital fibromatosis: a case report and review of the literature. Rare Tumors. 2009;1:e47.
4. Oh CK, Son HS, Kwon YW, et al. Intralesional fluorouracil injection in infantile digital fibromatosis. Arch Dermatol. 2005;141:549-550
5. Holmes WJ, Mishra A, McArthur P. Intra-lesional steroid for the management of symptomatic infantile digital fibromatosis. J Plast Reconstr Aesthet Surg. 2011;64:632-637.
6. Campbell LB, Petrick MG. Mohs micrographic surgery for a problematic infantile digital fibroma. Dermatol Surg. 2007;33:385-387.
7. Albertini JG, Welsch MJ, Conger LA, et al. Infantile digital fibroma treated with Mohs micrographic surgery. Dermatol Surg. 2002;28:959-961.
8. Kang SK, Chang SE, Choi JH, et al. A case of congenital infantile digital fibromatosis. Pediatr Dermatol. 2002;19:462-463.
9. Rimareix F, Bardot J, Andrac L, et al. Infantile digital fibroma—report on eleven cases. Eur J Pediatr Surg. 1997;7:345-348.
1. Heymann WR. Infantile digital fibromatosis. J Am Acad Dermatol. 2008;59:122-123.
2. Niamba P, Léauté-Labrèze C, Boralevi F, et al. Further documentation of spontaneous regression of infantile digital fibromatosis. Pediatr Dermatol. 2007;24:280-284.
3. Failla V, Wauters O, Nikkels-Tassoudji N, et al. Congenital infantile digital fibromatosis: a case report and review of the literature. Rare Tumors. 2009;1:e47.
4. Oh CK, Son HS, Kwon YW, et al. Intralesional fluorouracil injection in infantile digital fibromatosis. Arch Dermatol. 2005;141:549-550
5. Holmes WJ, Mishra A, McArthur P. Intra-lesional steroid for the management of symptomatic infantile digital fibromatosis. J Plast Reconstr Aesthet Surg. 2011;64:632-637.
6. Campbell LB, Petrick MG. Mohs micrographic surgery for a problematic infantile digital fibroma. Dermatol Surg. 2007;33:385-387.
7. Albertini JG, Welsch MJ, Conger LA, et al. Infantile digital fibroma treated with Mohs micrographic surgery. Dermatol Surg. 2002;28:959-961.
8. Kang SK, Chang SE, Choi JH, et al. A case of congenital infantile digital fibromatosis. Pediatr Dermatol. 2002;19:462-463.
9. Rimareix F, Bardot J, Andrac L, et al. Infantile digital fibroma—report on eleven cases. Eur J Pediatr Surg. 1997;7:345-348.
A 6-month-old male infant presented with a 1×0.5-cm, flesh-colored nodule on the dorsolateral aspect of the left second toe. The persistent, slowly enlarging, painless lesion was first noticed at 3 months of age and did not cause functional impairment. There was no preceding trauma and the patient’s medical history was otherwise noncontributory.
What Is Your Diagnosis? New World Cutaneous Leishmaniasis
A 40-year-old man presented with a nonhealing ulcer on the right hand of 2 months’ duration. The lesion had started as a pruritic papule while he was visiting Guyana 2 months prior. The area had slowly enlarged with progressive ulceration. He denied any systemic signs including fever, chills, or weight loss, and his medical history was unremarkable. Physical examination revealed a 4-cm fungating ulceration with heaped-up borders on the dorsal aspect of the right hand.
The Diagnosis: New World Cutaneous Leishmaniasis
In addition to the ulceration on the right hand, a 2-cm ulcerated plaque also had developed on the right side of the chin a few days later (Figure 1). A biopsy was obtained from the lesion on the hand. Histopathologic examination revealed granulomatous inflammation with numerous histiocytes containing intracellular organisms (Figure 2). The microorganisms had pale pink nuclei with basophilic kinetoplasts (Figure 3). Tissue culture showed a mixed growth of gram-positive and gram-negative organisms but no predominant organism. Fungal and mycobacterial cultures were negative. A diagnosis of New World cutaneous leishmaniasis (CL) was made due to visualization of intracellular microorganisms containing basophilic kinetoplasts. Polymerase chain reaction on the tissue block confirmed the presence of Leishmania guyanensis.
|
Cutaneous leishmaniasis is caused by protozoa from the Leishmania species and is transmitted by the bite of the female sandfly. There are 2 classifications for the disease: Old World and New World. Old World CL is transmitted by the sandfly of the genus Phlebotomus, which is endemic in Asia, Africa, the Mediterranean, and the Middle East. New World CL is transmitted by the sandflies of the genus Lutzomyia, which are endemic in Mexico, Central America, and South America. There have been occasional cases of autochthonous transmission reported in Texas and Oklahoma,1 but there has been no known transmission of CL in Australia or the Pacific Islands.2 Human infection can be transmitted by 21 species of Leishmania and can be speciated by designated laboratories such as the US Centers for Disease Control and Prevention (CDC) and the Walter Reed Army Institute of Research (Silver Spring, Maryland) using tissue culture and polymerase chain reaction.1 The CDC can assist with the collection of specimens and supply of culture medium for cases occurring in the United States. Identification of the species is important because there are associated implications for treatment and prognosis.
There are 3 major forms of leishmaniasis: cutaneous, mucocutaneous, and visceral. Cutaneous leishmaniasis is the most common form. There are approximately 1.5 million new cases of CL each year worldwide,3 and more than 90% of these cases occur in Afghanistan, Algeria, Iran, Iraq, Saudi Arabia, Syria, Brazil, and Peru.1 New World CL is caused by 2 species complexes: Leishmania mexicana and Leishmania viannia, including the subspecies L guyanensis, which was seen in our patient.
Cutaneous leishmaniasis usually begins as a small, well-defined papule at the site of the insect bite that then enlarges and becomes a nodule or plaque. Next, the lesion becomes ulcerated with raised borders (Figure 1). The ulcer typically is painless unless there is secondary bacterial or fungal infection.3,4 The incubation period usually is 2 to 8 weeks and multiple lesions may be present, as seen in our patient.4
Old World CL can resolve without treatment, but New World CL is less likely to spontaneously resolve. Additionally, there is a greater risk for spread of the infection to mucous membranes or for systemic dissemination if New World CL is left untreated.2,5 Patients with multiple lesions (ie, ≥3); large lesions (ie, >2.5 cm); lesions on the face, hands, feet, or joints; and those who are immunocompromised should be treated promptly.2 Pentavalent antimonials (eg, meglumine antimoniate, sodium stibogluconate) are the treatment of choice for New World CL, except for infections caused by L guyanensis. The most common pentavalent antimonial agent used in the United States is sodium stibogluconate and is given at a standard intravenous dose of 20 mg antimony/kg daily for 20 days.2 The drug is only available through the CDC’s Drug Service under an Investigational New Drug protocol.1
Intramuscular pentamidine (3 mg/kg daily every other day for 4 doses) is the first-line treatment of CL caused by L guyanensis because systemic antimony usually is not effective.2,6,7 Intralesional injection with pentavalent antimonials usually is not recommended for treatment of New World CL because of the possibility of disseminated disease.2 Liposomal amphotericin B has mainly been used to treat visceral and mucosal leishmaniasis, but there have been some small studies and case reports that have showed it to be successful in treating CL.8-10 Larger controlled studies need to be performed. Oral antifungal drugs (eg, fluconazole, ketoconazole, itraconazole) also have been used to treat CL with variable results depending on the Leishmania species.11
There currently are no vaccines or drugs available to prevent against leishmaniasis. Preventive measures such as avoiding outdoor activities from dusk to dawn when sandflies are the most active, wearing protective clothing, and applying insect repellent that contains DEET (diethyltoluamide) can help reduce a traveler’s risk for becoming infected. Mosquito nets also should be treated with permethrin, which acts as an insect repellent, as sandflies are so small that they can penetrate mosquito nets.1,3,11
Acknowledgements—We would like to thank Francis Steurer, MS, and Barbara Herwaldt, MD, MPH, at the CDC in Atlanta, Georgia, for their help with the identification of the Leishmania species.
1. Herwaldt BL, Magill AJ. Infectious diseases related to travel: leishmaniasis, cutaneous. Centers for Disease Control and Prevention Web site. http://wwwnc.cdc.gov/travel/yellowbook/2010/chapter-5/cutaneous-leish maniasis.htm. Published August 1, 2013. Accessed March 5, 2015.
2. Mitropolos P, Konidas P, Durkin-Konidas M. New World cutaneous leishmaniasis: updated review of current and future diagnosis and treatment. J Am Acad Dermatol. 2010;63:309-322.
3. Hepburn NC. Cutaneous leishmaniasis: an overview. J Postgrad Med. 2003;49:50-54.
4. Markle WH, Makhoul K. Cutaneous leishmaniasis: recognition and treatment. Am Fam Physician. 2004;69:1455-1460.
5. Couppié P, Clyti E, Sainte Marie D, et al. Disseminated cutaneous leishmaniasis due to Leishmania guyanensis: case of a patient with 425 lesions. Am J Trop Med Hyg. 2004;71:558-560.
6. Nacher M, Carme B, Sainte Marie D, et al. Influence of clinical presentation on the efficacy of a short course of pentamidine in the treatment of cutaneous leishmaniasis in French Guiana. Ann Trop Med Parasitol. 2001;95:331-336.
7. Minodier P, Parola P. Cutaneous leishmaniasis treatment. Trav Med Inf Dis. 2007;5:150-158.
8. Solomon M, Baum S, Barzilai A, et al. Liposomal amphotericin B in comparison to sodium stibogluconate for cutaneous infection due to Leishmania braziliensis. J Am Acad Dermatol. 2007;56:612-616.
9. Konecny P, Stark DJ. An Australian case of New World cutaneous leishmaniasis. Med J Aust. 2007;186:315-317.
10. Brown M, Noursadeghi M, Boyle J, et al. Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis. Br J Dermatol. 2005;153:203-205.
11. Parasites: leishmaniasis. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/parasites/leishmaniasis/index.html. Updated January 10, 2013. Accessed March 5, 2015.
A 40-year-old man presented with a nonhealing ulcer on the right hand of 2 months’ duration. The lesion had started as a pruritic papule while he was visiting Guyana 2 months prior. The area had slowly enlarged with progressive ulceration. He denied any systemic signs including fever, chills, or weight loss, and his medical history was unremarkable. Physical examination revealed a 4-cm fungating ulceration with heaped-up borders on the dorsal aspect of the right hand.
The Diagnosis: New World Cutaneous Leishmaniasis
In addition to the ulceration on the right hand, a 2-cm ulcerated plaque also had developed on the right side of the chin a few days later (Figure 1). A biopsy was obtained from the lesion on the hand. Histopathologic examination revealed granulomatous inflammation with numerous histiocytes containing intracellular organisms (Figure 2). The microorganisms had pale pink nuclei with basophilic kinetoplasts (Figure 3). Tissue culture showed a mixed growth of gram-positive and gram-negative organisms but no predominant organism. Fungal and mycobacterial cultures were negative. A diagnosis of New World cutaneous leishmaniasis (CL) was made due to visualization of intracellular microorganisms containing basophilic kinetoplasts. Polymerase chain reaction on the tissue block confirmed the presence of Leishmania guyanensis.
|
Cutaneous leishmaniasis is caused by protozoa from the Leishmania species and is transmitted by the bite of the female sandfly. There are 2 classifications for the disease: Old World and New World. Old World CL is transmitted by the sandfly of the genus Phlebotomus, which is endemic in Asia, Africa, the Mediterranean, and the Middle East. New World CL is transmitted by the sandflies of the genus Lutzomyia, which are endemic in Mexico, Central America, and South America. There have been occasional cases of autochthonous transmission reported in Texas and Oklahoma,1 but there has been no known transmission of CL in Australia or the Pacific Islands.2 Human infection can be transmitted by 21 species of Leishmania and can be speciated by designated laboratories such as the US Centers for Disease Control and Prevention (CDC) and the Walter Reed Army Institute of Research (Silver Spring, Maryland) using tissue culture and polymerase chain reaction.1 The CDC can assist with the collection of specimens and supply of culture medium for cases occurring in the United States. Identification of the species is important because there are associated implications for treatment and prognosis.
There are 3 major forms of leishmaniasis: cutaneous, mucocutaneous, and visceral. Cutaneous leishmaniasis is the most common form. There are approximately 1.5 million new cases of CL each year worldwide,3 and more than 90% of these cases occur in Afghanistan, Algeria, Iran, Iraq, Saudi Arabia, Syria, Brazil, and Peru.1 New World CL is caused by 2 species complexes: Leishmania mexicana and Leishmania viannia, including the subspecies L guyanensis, which was seen in our patient.
Cutaneous leishmaniasis usually begins as a small, well-defined papule at the site of the insect bite that then enlarges and becomes a nodule or plaque. Next, the lesion becomes ulcerated with raised borders (Figure 1). The ulcer typically is painless unless there is secondary bacterial or fungal infection.3,4 The incubation period usually is 2 to 8 weeks and multiple lesions may be present, as seen in our patient.4
Old World CL can resolve without treatment, but New World CL is less likely to spontaneously resolve. Additionally, there is a greater risk for spread of the infection to mucous membranes or for systemic dissemination if New World CL is left untreated.2,5 Patients with multiple lesions (ie, ≥3); large lesions (ie, >2.5 cm); lesions on the face, hands, feet, or joints; and those who are immunocompromised should be treated promptly.2 Pentavalent antimonials (eg, meglumine antimoniate, sodium stibogluconate) are the treatment of choice for New World CL, except for infections caused by L guyanensis. The most common pentavalent antimonial agent used in the United States is sodium stibogluconate and is given at a standard intravenous dose of 20 mg antimony/kg daily for 20 days.2 The drug is only available through the CDC’s Drug Service under an Investigational New Drug protocol.1
Intramuscular pentamidine (3 mg/kg daily every other day for 4 doses) is the first-line treatment of CL caused by L guyanensis because systemic antimony usually is not effective.2,6,7 Intralesional injection with pentavalent antimonials usually is not recommended for treatment of New World CL because of the possibility of disseminated disease.2 Liposomal amphotericin B has mainly been used to treat visceral and mucosal leishmaniasis, but there have been some small studies and case reports that have showed it to be successful in treating CL.8-10 Larger controlled studies need to be performed. Oral antifungal drugs (eg, fluconazole, ketoconazole, itraconazole) also have been used to treat CL with variable results depending on the Leishmania species.11
There currently are no vaccines or drugs available to prevent against leishmaniasis. Preventive measures such as avoiding outdoor activities from dusk to dawn when sandflies are the most active, wearing protective clothing, and applying insect repellent that contains DEET (diethyltoluamide) can help reduce a traveler’s risk for becoming infected. Mosquito nets also should be treated with permethrin, which acts as an insect repellent, as sandflies are so small that they can penetrate mosquito nets.1,3,11
Acknowledgements—We would like to thank Francis Steurer, MS, and Barbara Herwaldt, MD, MPH, at the CDC in Atlanta, Georgia, for their help with the identification of the Leishmania species.
A 40-year-old man presented with a nonhealing ulcer on the right hand of 2 months’ duration. The lesion had started as a pruritic papule while he was visiting Guyana 2 months prior. The area had slowly enlarged with progressive ulceration. He denied any systemic signs including fever, chills, or weight loss, and his medical history was unremarkable. Physical examination revealed a 4-cm fungating ulceration with heaped-up borders on the dorsal aspect of the right hand.
The Diagnosis: New World Cutaneous Leishmaniasis
In addition to the ulceration on the right hand, a 2-cm ulcerated plaque also had developed on the right side of the chin a few days later (Figure 1). A biopsy was obtained from the lesion on the hand. Histopathologic examination revealed granulomatous inflammation with numerous histiocytes containing intracellular organisms (Figure 2). The microorganisms had pale pink nuclei with basophilic kinetoplasts (Figure 3). Tissue culture showed a mixed growth of gram-positive and gram-negative organisms but no predominant organism. Fungal and mycobacterial cultures were negative. A diagnosis of New World cutaneous leishmaniasis (CL) was made due to visualization of intracellular microorganisms containing basophilic kinetoplasts. Polymerase chain reaction on the tissue block confirmed the presence of Leishmania guyanensis.
|
Cutaneous leishmaniasis is caused by protozoa from the Leishmania species and is transmitted by the bite of the female sandfly. There are 2 classifications for the disease: Old World and New World. Old World CL is transmitted by the sandfly of the genus Phlebotomus, which is endemic in Asia, Africa, the Mediterranean, and the Middle East. New World CL is transmitted by the sandflies of the genus Lutzomyia, which are endemic in Mexico, Central America, and South America. There have been occasional cases of autochthonous transmission reported in Texas and Oklahoma,1 but there has been no known transmission of CL in Australia or the Pacific Islands.2 Human infection can be transmitted by 21 species of Leishmania and can be speciated by designated laboratories such as the US Centers for Disease Control and Prevention (CDC) and the Walter Reed Army Institute of Research (Silver Spring, Maryland) using tissue culture and polymerase chain reaction.1 The CDC can assist with the collection of specimens and supply of culture medium for cases occurring in the United States. Identification of the species is important because there are associated implications for treatment and prognosis.
There are 3 major forms of leishmaniasis: cutaneous, mucocutaneous, and visceral. Cutaneous leishmaniasis is the most common form. There are approximately 1.5 million new cases of CL each year worldwide,3 and more than 90% of these cases occur in Afghanistan, Algeria, Iran, Iraq, Saudi Arabia, Syria, Brazil, and Peru.1 New World CL is caused by 2 species complexes: Leishmania mexicana and Leishmania viannia, including the subspecies L guyanensis, which was seen in our patient.
Cutaneous leishmaniasis usually begins as a small, well-defined papule at the site of the insect bite that then enlarges and becomes a nodule or plaque. Next, the lesion becomes ulcerated with raised borders (Figure 1). The ulcer typically is painless unless there is secondary bacterial or fungal infection.3,4 The incubation period usually is 2 to 8 weeks and multiple lesions may be present, as seen in our patient.4
Old World CL can resolve without treatment, but New World CL is less likely to spontaneously resolve. Additionally, there is a greater risk for spread of the infection to mucous membranes or for systemic dissemination if New World CL is left untreated.2,5 Patients with multiple lesions (ie, ≥3); large lesions (ie, >2.5 cm); lesions on the face, hands, feet, or joints; and those who are immunocompromised should be treated promptly.2 Pentavalent antimonials (eg, meglumine antimoniate, sodium stibogluconate) are the treatment of choice for New World CL, except for infections caused by L guyanensis. The most common pentavalent antimonial agent used in the United States is sodium stibogluconate and is given at a standard intravenous dose of 20 mg antimony/kg daily for 20 days.2 The drug is only available through the CDC’s Drug Service under an Investigational New Drug protocol.1
Intramuscular pentamidine (3 mg/kg daily every other day for 4 doses) is the first-line treatment of CL caused by L guyanensis because systemic antimony usually is not effective.2,6,7 Intralesional injection with pentavalent antimonials usually is not recommended for treatment of New World CL because of the possibility of disseminated disease.2 Liposomal amphotericin B has mainly been used to treat visceral and mucosal leishmaniasis, but there have been some small studies and case reports that have showed it to be successful in treating CL.8-10 Larger controlled studies need to be performed. Oral antifungal drugs (eg, fluconazole, ketoconazole, itraconazole) also have been used to treat CL with variable results depending on the Leishmania species.11
There currently are no vaccines or drugs available to prevent against leishmaniasis. Preventive measures such as avoiding outdoor activities from dusk to dawn when sandflies are the most active, wearing protective clothing, and applying insect repellent that contains DEET (diethyltoluamide) can help reduce a traveler’s risk for becoming infected. Mosquito nets also should be treated with permethrin, which acts as an insect repellent, as sandflies are so small that they can penetrate mosquito nets.1,3,11
Acknowledgements—We would like to thank Francis Steurer, MS, and Barbara Herwaldt, MD, MPH, at the CDC in Atlanta, Georgia, for their help with the identification of the Leishmania species.
1. Herwaldt BL, Magill AJ. Infectious diseases related to travel: leishmaniasis, cutaneous. Centers for Disease Control and Prevention Web site. http://wwwnc.cdc.gov/travel/yellowbook/2010/chapter-5/cutaneous-leish maniasis.htm. Published August 1, 2013. Accessed March 5, 2015.
2. Mitropolos P, Konidas P, Durkin-Konidas M. New World cutaneous leishmaniasis: updated review of current and future diagnosis and treatment. J Am Acad Dermatol. 2010;63:309-322.
3. Hepburn NC. Cutaneous leishmaniasis: an overview. J Postgrad Med. 2003;49:50-54.
4. Markle WH, Makhoul K. Cutaneous leishmaniasis: recognition and treatment. Am Fam Physician. 2004;69:1455-1460.
5. Couppié P, Clyti E, Sainte Marie D, et al. Disseminated cutaneous leishmaniasis due to Leishmania guyanensis: case of a patient with 425 lesions. Am J Trop Med Hyg. 2004;71:558-560.
6. Nacher M, Carme B, Sainte Marie D, et al. Influence of clinical presentation on the efficacy of a short course of pentamidine in the treatment of cutaneous leishmaniasis in French Guiana. Ann Trop Med Parasitol. 2001;95:331-336.
7. Minodier P, Parola P. Cutaneous leishmaniasis treatment. Trav Med Inf Dis. 2007;5:150-158.
8. Solomon M, Baum S, Barzilai A, et al. Liposomal amphotericin B in comparison to sodium stibogluconate for cutaneous infection due to Leishmania braziliensis. J Am Acad Dermatol. 2007;56:612-616.
9. Konecny P, Stark DJ. An Australian case of New World cutaneous leishmaniasis. Med J Aust. 2007;186:315-317.
10. Brown M, Noursadeghi M, Boyle J, et al. Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis. Br J Dermatol. 2005;153:203-205.
11. Parasites: leishmaniasis. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/parasites/leishmaniasis/index.html. Updated January 10, 2013. Accessed March 5, 2015.
1. Herwaldt BL, Magill AJ. Infectious diseases related to travel: leishmaniasis, cutaneous. Centers for Disease Control and Prevention Web site. http://wwwnc.cdc.gov/travel/yellowbook/2010/chapter-5/cutaneous-leish maniasis.htm. Published August 1, 2013. Accessed March 5, 2015.
2. Mitropolos P, Konidas P, Durkin-Konidas M. New World cutaneous leishmaniasis: updated review of current and future diagnosis and treatment. J Am Acad Dermatol. 2010;63:309-322.
3. Hepburn NC. Cutaneous leishmaniasis: an overview. J Postgrad Med. 2003;49:50-54.
4. Markle WH, Makhoul K. Cutaneous leishmaniasis: recognition and treatment. Am Fam Physician. 2004;69:1455-1460.
5. Couppié P, Clyti E, Sainte Marie D, et al. Disseminated cutaneous leishmaniasis due to Leishmania guyanensis: case of a patient with 425 lesions. Am J Trop Med Hyg. 2004;71:558-560.
6. Nacher M, Carme B, Sainte Marie D, et al. Influence of clinical presentation on the efficacy of a short course of pentamidine in the treatment of cutaneous leishmaniasis in French Guiana. Ann Trop Med Parasitol. 2001;95:331-336.
7. Minodier P, Parola P. Cutaneous leishmaniasis treatment. Trav Med Inf Dis. 2007;5:150-158.
8. Solomon M, Baum S, Barzilai A, et al. Liposomal amphotericin B in comparison to sodium stibogluconate for cutaneous infection due to Leishmania braziliensis. J Am Acad Dermatol. 2007;56:612-616.
9. Konecny P, Stark DJ. An Australian case of New World cutaneous leishmaniasis. Med J Aust. 2007;186:315-317.
10. Brown M, Noursadeghi M, Boyle J, et al. Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis. Br J Dermatol. 2005;153:203-205.
11. Parasites: leishmaniasis. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/parasites/leishmaniasis/index.html. Updated January 10, 2013. Accessed March 5, 2015.